Epigenetic Phosphorylation Control of *Mycobacterium tuberculosis* Infection and Persistence

26

Melissa Richard-Greenblatt and Yossef Av-Gay

PROTEIN PHOSPHORYLATION IN *MYCOBACTERIUM TUBERCULOSIS*

Protein phosphorylation is known to occur across all three kingdoms of life; however, the study of posttranslational modification in bacteria was neglected for a considerable amount of time. Early attempts to detect its presence were unsuccessful, generating the dogma that protein phosphorylation was a regulatory mechanism that emerged late in evolution to meet the needs of organisms composed of multiple and differentiated cells. The pioneering work of several groups in the 1970s identified protein kinase activity in both *Escherichia coli* and *Salmonella typhimurium* (1–3), which soon led to the discovery of the histidine/aspartate kinases of the two-component systems (4, 5). The first aspect of this system involves the stimulation of a histidine kinase by a particular environmental or intracellular signal resulting in autophosphorylation on a key histidine residue. The phospho-histidine can then be used as a substrate by the cognate response regulator for its own autophosphorylation on an aspartate residue. The majority of response regulators are DNA binding proteins that trigger expression from target promoters. Unlike the cross-reactivity observed with serine/threonine/tyrosine (Ser/Thr/Tyr) kinases in eukaryotic cell signaling cascades, two-component systems work in isolation, where a given pairing of histidine kinase and response regulator is highly selective for each other via protein-protein interaction.

During the initial phase of the two-component system discovery, these systems were regarded as the major signal transduction pathway in bacteria, which led to the hypothesis that Ser/Thr/Tyr phosphorylation was a eukaryotic trait, whereas His/Asp phosphorylation was exclusive to prokaryotes. Since this time, our knowledge of protein phosphorylation has been revised. Hundreds of two-component systems have been discovered in eukaryotic cells (6), and recent genomic data indicate that "eukaryotic-like" Ser/Thr protein kinases (STPKs) are as prevalent in prokaryotes as in their histidine kinase counterparts (7). However, two-component systems remain the main signaling mechanism in all phyla of bacteria, with STPKs most abundant among *Acidobacteria*, *Actinobacteria* (including the genus *Mycobacterium*), various groups of *Cyanobacteria*, as well as bacteria belonging to the order of *Myxococcales*.

The pathogenic success of *M. tuberculosis* is largely dependent on its ability to sense and adapt to the dynamic environment of the host. As a result, *M. tuberculosis* has evolved an extensive intracellular signaling network consisting of 12 paired two-component regulatory systems (also including 4 orphan regulators), 11 STPKs, a single tyrosine kinase, and 3 phosphatases, which have been extensively reviewed in the past 2 decades (8–10). The presence of Ser/Thr and Tyr protein kinases, and two-component systems that phosphorylate substrates on Asp, enables the cell to generate phosphorylated residues with far greater stability. Generally, the hydrolytic half-time of phosphoryl-asp is only a couple of hours, whereas Ser/Thr/Tyr phosphor-esters, or *O*-phosphorylation, can produce signals that remain stable for weeks and require a phosphatase to be reversed (11). Consequently, *M. tuberculosis* uses phosphoryl-asp for rapid, short-term signal transduction and Ser/Thr/Tyr phosphorylation for long-term,

Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.

Table 1   Biochemically verified substrates of *M. tuberculosis* serine/threonine protein kinases[a]

Kinase	Substrate function	Substrate
PknA (Rv0015c)	Cell division	FipA (179), FtsZ (85), ParB (180), Wag31 (66)
	Arabinan biosynthesis	EmbR (181)
	MA biosynthesis	KasA (101), KasB (101), FabD (101), FabH (102), HadAB/BC (99), InhA (97,98), MabA (96)
	PG biosynthesis	MurD (74)
	TCA cycle	Mdh (172)
	Methionine cycle	SahH (182)
	Signaling	PstP (183), PtkA (22)
	Protein chaperone	GroEL1 (184)
	Proteasome	PrcA (56)
	Hypothetical	Rv1422/CuvA (66)
PknB (Rv0014c)	Cell division	HupB (185), ParB (180)
	Arabinan biosynthesis	EmbR (181)
	MA biosynthesis	KasA (101), KasB (101), FabD (101), HadAB/BC (99), InhA (97, 98), MabA (96)
	PG biosynthesis	FhaA (186, 187), GlmU (67), MviN (68), PbpA (87), PonA1 (79)
	α-Glucan biosynthesis	GlgE (143)
	PDIM biosynthesis	PapA5 (115, 116)
	Erothioneine biosynthesis	EgtD (132)
	TCA cycle	GarA (40, 167, 188)
	Methionine cycle	SahH (182, 189)
	Signaling	PstP (183), PtpA (51)
	Protein chaperone	GroEL1 (184)
	Protein synthesis	EF-Tu (190)
	Proteasome	PrcA (56)
	Stress response	RshA (55), SigH (55)
	Hypothetical	Rv1422/CuvA (66), Rv0516c (30), Rv1747 (186)
PknD (Rv0931c)	Cell division	ParB (180)
	MA biosynthesis	FabD (101), FabH (102), HadAB/BC (99), KasA (101), KasB (101), MabA (96), PcaA (191)
	Ergothioneine biosynthesis	EgtD (132)
	TCA cycle	GarA (188), Mdh (172)
	Signaling	PtkA (22), PtpA (51)
	Protein chaperone	GroEL1 (184)
	Transport	MmpL7 (114), Rv1747 (186)
	Osmotic stress	OprA (30)
	Anti-antisigma factor?	Rv0516c (30)
PknE (Rv1743)	Cell division	HupB (185)
	Arabinan biosynthesis	EmbR (192), EmbR2 (192)
	MA biosynthesis	FabD (101), FabH (96), KasA (101), KasB (101), HadAB/BC (99), PcaA (191)
	PDIM biosynthesis	PapA5 (115)
	TCA cycle	GarA (188), Mdh (172)
	Methionine cycle	SahH (182)
	Signaling	PtpA (51)
	Protein chaperone	GroEL1 (184)
	Transport	Rv1747 (186)
	Stress response	RshA (30)
	Anti-antisigma factor	RsfA (30), Rv0516c (30), Rv1904 (30)
PknF (Rv1746)	Cell division	HupB (185), ParB (180)
	Arabinan biosynthesis	EmbR (192), EmbR2 (192)
	MA biosynthesis	FabD (101), FabH (96), KasA (101), KasB (101), HadAB/BC (99), InhA (98), PcaA (191)
	PG biosynthesis	FhaA (186)

(Continued)

Table 1 *(Continued)*

Kinase	Substrate function	Substrate
	TCA cycle	GarA (188)
	Methionine cycle	SahH (182)
	Signaling	PtkA (22)
	Protein chaperone	GroE1 (184)
	Transport	Rv1747 (164)
PknG (Rv0410c)	TCA cycle	GarA (40, 167), Mdh (172)
	Oxidative stress/biofilm growth	L13 (193)
PknH (Rv1266c)	Arabinan biosynthesis	EmbR (25, 194)
	MA biosynthesis	FadD (101), FabH (102), HadAB/BC (99), InhA (98), KasA (101), KasB (101), PcaA (191)
	PG biosynthesis	DacB1 (78)
	TCA cycle	Mdh (172)
	Methionine cycle	SahH (182)
	Signaling	PtpA (51)
	Protein chaperone	GroEL1 (184)
	Dormancy	DosR (27)
	Transcription	Rv0681 (78)
PknI (Rv2914c)	MA biosynthesis	FadD (101)
PknJ (Rv2088)	Arabinan biosynthesis	EmbR (195)
	MA biosynthesis	MmaA4 (195)
	TCA cycle	Mdh (172)
	Glycolysis	PykA (162, 165)
	Dipeptidase	PepE (195)
PknK (Rv3080c)	MA biosynthesis	FabD (196), VirS (14)
	Ergothioneine biosynthesis	EgtD (132)
	Signaling	PtkA (22)
PknL (Rv2176)	MA biosynthesis	FadD (101), InhA (97), KasA (101), KasB (101), MabA (96)
	Protein chaperone	GroEL1 (184)
	Methionine cycle	SahH (182)
	Signaling	PtpA (51)
	DNA binding?	Rv2175c (197)

*a*Abbreviations: MA, mycolic acid; PG, peptidoglycan biosynthesis; TCA, tricarboxylic acid.

global responses, giving cells the advantage to adapt and survive in complex environments.

The discovery of *M. tuberculosis* STPKs originated from the identification of 11 genes encoding for the subdomains of the Hank's superfamily of kinases, resulting in their annotation as "eukaryotic-like" STPKs (12). Yet it is possible that not all STPKs involved in *O*-phosphorylation have been identified due to our use of a eukaryotic-like biased paradigm. Of the 11 STPKs (PknA to PknL, with the exception of PknC), the sequences of 9 contain a transmembrane region that connects the intracellular N-terminal kinase domain to a C-terminal sensory component located extracellularly. Current structural data indicate that these transmembrane receptor kinases are activated by dimerization of their kinase domains, resulting in the phosphorylation of the activation loop and ultimately leading to kinase activation (13). The remaining two

kinases, PknK and PknG, lack a transmembrane domain. Yet subcellular fractions of *M. tuberculosis* lysates showed PknK to be present in the cell wall/membrane fraction rather than the cytosol through an unknown anchoring mechanism (14). Therefore, PknG is described as the sole soluble STPK in *M. tuberculosis*.

Due to the lack of Tyr kinases in the *M. tuberculosis* genome, Tyr phosphorylation was believed to be absent from *M. tuberculosis* despite the presence of two protein Tyr phosphatases: PtpA and PtpB (15). As a result, these protein phosphatases were originally hypothesized to be solely involved in the interference of host signaling pathways, which was shown by the ability of PtpA to inhibit host vesicular trafficking and phagosome acidification (16, 17). However, preliminary immunoblot evidence suggesting the existence of an *M. tuberculosis* protein phosphorylated on Tyr (18) led us to identify the first *M. tuberculosis* protein tyrosine

kinase, PtkA, located within the same operon as its cognate substrate PtpA (19). Recent phosphoproteomic data have indeed found *M. tuberculosis* to support extensive Tyr phosphorylation (63 sites on 49 proteins) (20). Yet bioinformatic analysis has been unsuccessful in identifying any of the traditional bacterial tyrosine kinases (known as BY-kinases), suggesting that Tyr phosphorylation might be carried out strictly by a novel and "odd" family of Tyr kinases in *M. tuberculosis* (21). However, recent investigation by Kusebauch et al. (20) found that *M. tuberculosis* STPKs undergo Tyr phosphorylation in their activation segment, suggesting their action as dual-specificity (Ser/Thr/Tyr) kinases. Although plausible, this hypothesis has to be proven experimentally because none of the STPKs have been shown to phosphorylate their substrates on Tyr. On the other hand, the tyrosine kinase PtkA was shown to be Ser/Thr phosphorylated by and interact with several STPKs (22), strengthening the idea of cross-phosphorylation between STPKs and Tyr kinases in *M. tuberculosis*.

Similar to other prokaryotes, the overall extent of O-phosphorylation in *M. tuberculosis* is limited, amounting to 7.5% of all proteins being phosphorylated (23), compared to the 40 to 45% of eukaryotes (24). As expected, the number of Ser/Thr phosphorylation sites in *M. tuberculosis* is significantly greater than that of Tyr, with over 500 sites identified (23). These findings indicate that each STPK can act on multiple substrates (Table 1). However, little is known regarding STPK signaling cascades and kinase hierarchy in *M. tuberculosis*. In contrast to His-kinases, which typically phosphorylate a single response regulator, the cross-reactivity observed with Ser/Thr/Tyr kinases results in complex signaling cascades. Rarely does the direct output of *M. tuberculosis* Ser/Thr phosphorylation involve the direct regulation of expression of target genes; however, some evidence exists of signaling organization typical of two-component systems (14, 25–27).

Recently, *in vitro* analysis of the interactions between all STPKs has added a novel layer of signaling in *M. tuberculosis* (28). Mapping of STPK phosphorylation suggests a three-layered architecture that includes master regulator (PknB and PknH), signal transducer (PknE and PknJ), and terminal substrate kinases (PknA, PknD, PknF, PknK, and PknL) as shown in Fig. 1. Master regulator kinases exclusively undergo autophosphorylation to achieve activation, which can in turn cross-phosphorylate downstream kinases. Signal transducing kinases can also autophosphorylate as well as cross-phosphorylate downstream kinases, which is likely to act as a mode to propagate signals to intracel-

lular substrates. The remaining substrate kinases were unable to transfer phosphates to other STPKs, indicating that their molecular targets are limited to other protein substrates. Furthermore, four of these kinases (PknA, PknF, PknK, PknL) are thought to lack the machinery to detect extracellular signals and therefore rely on cross-phosphorylation by the upstream kinases for activation (28). Recent evidence showed PknA to autophosphorylate its own activation loop independent of PknB; however, the extracytoplasmic domain appears to be dispensable for PknA function (29). Unlike the other substrate kinases, PknD contains an extracellular β-propeller used by *M. tuberculosis* to sense osmotic stress and is also strategically positioned in the intracellular signaling network to regulate the "stressosome" in response to upstream STPKs (30–32). However, little is known about which ligands bind to these sensor domains or about what environmental stimuli they respond to (Table 2). Furthermore, it is evident that transcriptional data offer limited information about the environmental cues that are sensed by *M. tuberculosis* STPKs. Conditions have been reported where the transcriptional levels of STPKs have increased and meanwhile their protein levels remained unchanged (33). Furthermore, STPKs require activation through auto- or cross-phosphorylation prior to initiating any downstream signaling events. Therefore, it is recommended that caution be used when inferring relationships between environmental conditions and STPK function.

Our understanding of bacterial signal transduction has become very significant due to its role in *M. tuberculosis* pathogenicity. In recent years, STPKs have been shown to play a crucial role in the growth and survival of *M. tuberculosis* during infection. The intracellular cascades induced by STPKs culminate in alterations in gene transcription, enzymatic activity, cellular localization, and protein-protein interactions which translate into the rapid metabolic adaptation of the bacterium. Through our knowledge of their corresponding environmental stimuli and substrates, along with the bacilli's physiological responses, we dedicate this article to describing the role of STPKs in the growth and/or survival of *M. tuberculosis* to establish a persistent infection.

ESTABLISHING INFECTION THROUGH SUBVERSION OF INNATE IMMUNE RESPONSE BY STPKs

Following internalization by host macrophages, *M. tuberculosis* resides and replicates in intracellular membrane-bound vacuoles. Bacterial compartmentalization

Figure 1 Hierarchy of *M. tuberculosis* STPK activation in response to extracellular and intracellular signals. Master STPKs (blue) sense environmental signals and further cross-phosphorylate the kinase domains of signal transducing (purple) and substrate (red) STPKs to propagate signals and regulate specific downstream proteins. (Figure modified from reference 28).

provides an enclosed space for the host cell to localize high concentrations of reactive oxygen species, reactive nitrogen intermediates, and enzymes that eliminate invading pathogens. Typically during infection, the phagosome fuses with endosomes and lysosomes, resulting in lumen acidification and the acquisition of proteolytic enzymes for lysosome-mediated degradation of invading microorganisms. The classical mechanism *M. tuberculosis* uses to evade the innate immune response is through inhibition of these cellular pathways, namely, phagosomal acidification and blockage of the fusion of phagosomes with lysosomes (34, 35). Therefore, sensing the intracellular environment of the macrophage, adapting its physiology, and responding to host defense mechanisms are an integral part of *M. tuberculosis* pathophysiology.

One of the fascinating strategies used by *M. tuberculosis* is its recently discovered ability to directly in-

terfere with host signaling pathways. The best and first studied example of such interference is the utilization of the mycobacterial secreted Tyr phosphatase PtpA. PtpA was shown to possess phosphatase activity against the host vacuolar protein sorting 33B and glycogen synthase kinase-α, resulting in the arrest of phagosome maturation and prevention of macrophage apoptosis, respectively (16, 36). In addition, PtpA binds subunit H of the macrophage ATPase pump, resulting in blockage of phagosomal acidification and leading to subversion of one of the key characteristics of innate immunity (37, 38).

Inhibition of Phagosome-Lysosome Fusion
M. tuberculosis STPKs are mainly localized to the mycobacterial membrane, and as such possess a limited role in the direct interaction with the host immune system. The only exception described has been that of PknG,

Table 2 Growth and persistence phenotypes of *M. tuberculosis* serine/threoneine protein kinase mutants[a]

STPK	*In vitro*[b]	Other *in vitro* conditions[c]	*Ex vivo* survival	*In vivo* survival
PknA[d]	Essential (29)			Negligible histopathology, no bacilli recovered from lung or spleen of mice (88)
PknB[d]	Essential (88)			Negligible histopathology, no bacilli recovered from lung or spleen of mice (88)
PknD	N.D. (198)	↓ P_i poor conditions following 24 h starvation (199)	N.D. murine macrophages (173)	Required for invasion of brain endothelia (173) N.D. lungs for mouse or guinea pig (198)
PknE	N.D. (43)	↓ DTT, glutathione, zinc, cadmium, ↑ SNP, GSNO, acidified nitrite (43)	↓ 120 h THP-1 cells (43)	↑ Guinea pigs (200)[e] N.D. BALB/c mice (44)
PknF[f]	Faster growth, shortened cells (163)			
PknG	↓ Exponential, more pronounced stationary (41)	↓ Nutrient depleted (41)		↓ Lung, spleen, and liver in BALB/c and CD-1 mice (41)
PknH	N.D. (44)	↑ Acidified nitrite stress ↓ H_2O_2, O_2^- (44)	↓ 120 h THP-1 cells (44)	↑ Lung and spleen in BALB/c mice (44)
PknI	↓ Exponential (135)	↑ Acidic pH and hypoxia ↓ Acidic pH and oxygenated (135)	↑ 120 h THP-1 cells (135)	Hypervirulent SCID mice (135)
PknK	N.D. exponential ↑ Stationary phase Shortened cells (133)	↑ Acidic pH, hypoxia, H_2O_2 (133)	–	↓ Acute phase lung, ↑ persistent phase lung and spleen in C57BL/6 (133)

[a]Abbreviations: DTT, dithiothreitol; SNP, sodium nitroprusside; GSNO, S-nitrosoglutathione; THP-1, human monocytic cell line derived from an acute monocytic leukemia patient; ND, no observed difference in phenotype.
[b]*In vitro* growth under nutrient-rich, oxygenated conditions based on optical density or CFU data.
[c]*In vitro* growth conditions showing STPK mutant phenotypes varying from wild type. Based on optical density or CFU data.
[d]*In vivo* work performed with conditional depletion mutant of PknA or PknB.
[e]Polar effect was not ruled out due to lack of complemented strain.
[f]Results represent work performed with a *pknF* antisense mutant.

which was shown to be secreted and suggested to directly phosphorylate host proteins (39). Although a direct host substrate was not yet identified, PknG was suggested to control phagosome-lysosome fusion of *Mycobacterium bovis* Bacille Calmette-Guérin (BCG)-containing phagosomes within macrophages (39), in contrast to *Mycobacterium smegmatis*, which was directly transferred to lysosomal compartments upon infection. However, PknG was shown to have a direct role in *M. tuberculosis* physiology (40). Since no host substrates or mechanism for PknG blockage of phagosome-lysosome fusion has been described, the effect on host response might be indirect and can be explained by the growth deficiency of the PknG mutant in macrophages and animal models (41).

Apoptosis

Consistent with *M. tuberculosis*'s ability to evade immune-mediated destruction, blockage of macrophage apoptosis upon infection enables bacterial persistence (42). PknE was shown to have a role in *M. tuberculosis* pathogenicity because the mutant demonstrated decreased survival due to increased host-apoptosis in both macrophage and murine models of infection (43, 44). In line with the role of nitric oxide (NO) in regulating the intrinsic apoptotic events of the cell (45), apoptosis occurred following treatment of the Δ*pknE* mutant with NO (43). Furthermore, *pknE* expression was shown to be upregulated in the presence of nitrate stress in *M. smegmatis*, although a polar effect of the mutation was not ruled out. Despite the study lacking a complement, these findings suggest that PknE senses NO inside the host and possibly interacts with other mycobacterial and/or host cell components, leading to inhibition of apoptosis.

The exact mechanism underlying the inhibition of apoptosis by PknE remains unknown; however, a role for PknE in modulating the expression of apoptotic proteins was suggested (46, 47). The *pknE* gene was shown to modulate the expression of Toll-like receptors (TLRs), in agreement with their previously identified role in *M. tuberculosis* infections, by regulating apoptosis and inflammatory responses (48, 49). In addition, a number of PknE substrates are involved in regulating mycolic acid synthesis (Table 1). The uptake of mycolic acids has been previously shown to prolong the survival and increase Bcl-2 expression of the macrophage (50). Furthermore, mycolic acid extracted from *M. tuberculosis* was also shown to reduce the macrophage response to TLR2 agonists, which could prevent the induction of apoptosis (48). Therefore, PknE may prevent apoptosis of the infected macrophage by altering

its cell wall to avoid triggering activation of TLRs associated with cell death.

Another potential mechanism by which PknE may be involved in blocking apoptosis is through regulation of PtpA, which has been shown to be a substrate of PknE (51). Several studies have described substrates of PtpA in the host and its ability to directly interfere with host cell signaling pathways (16, 36–38). Dephosphorylation of one of the PtpA substrates, GSK3α, was indeed shown to decrease apoptosis of the host cell early in infection (36). Furthermore, a kinome analysis identified additional substrates for PtpA, including other apoptotic proteins (36). Therefore, it would be of interest to determine if PknE is able to suppress apoptosis through the regulation of PtpA.

Defense Against Host-Generated Reactive Oxygen and Nitrogen Species

Although *M. tuberculosis* is able to avoid immune recognition, the bacterium is still required to overcome the hostile environment of the phagosome. Upon phagocytosis, *M. tuberculosis* is immediately exposed to a considerable amount of reactive oxygen species, while reactive nitrogen species levels only increase after 72 h (52).

The alternate sigma factor, SigH, is a central regulator of mycobacterial adaptation to redox, heat, and acid stress and is induced upon phagocytosis of the macrophage (53). In addition to undergoing autoregulation of its promoter, SigH interacts posttranslationally with its cognate antisigma factor, RshA (54). Under oxidizing conditions the interaction between RshA and SigH is disrupted, leading to a strong induction of the SigH regulon. However, if the regulation of SigH was employed by this mechanism alone, by the time the intracellular environment became significantly oxidized and RshA dissociated from SigH, damage to *M. tuberculosis* biomolecules would have already occurred. Therefore, the binding of RshA to SigH undergoes further kinase-mediated regulation by PknB, allowing *M. tuberculosis* to generate a more rapid response to an oxidative environment (55). To overcome challenge by oxidative stress, phosphorylation of RshA decreases its interaction with SigH *in vitro*, leading to increased SigH activity *in vivo*. In addition, phosphorylation of SigH was also demonstrated by PknB *in vitro*, but this modification had no effect on the SigH-RshA interaction. It is hypothesized that phosphorylation of SigH may alter binding or transcriptional activation at individual promoters under conditions of increased *pknB* expression; however, this remains to be determined.

In addition to PknB, PknA has also been shown to be involved in responding to oxidative stress. In the

presence of H_2O_2, PknA increases its autophosphorylation levels (56). The implication of the observed enhancement of PknA activation was specifically observed to hinder proteasome assembly. The α-subunit (PrcA) and β-subunit (pre-PrcB) of the *M. tuberculosis* proteasome core complex are phosphorylated by both PknB and PknA, with PknB phosphorylation leading to enhanced degradation of the proteasomal substrate, Ino1 (56, 57). In contrast, phosphorylation of PrcA by PknA did not affect the proteasomal degradation *in vitro*. Rather, phosphorylation of both pre-PrcB and PrcA by H_2O_2-induced PknA activation inhibited the assembly of the holo-proteasome complex. Depletion of the proteasomal system was originally found to impair *M. tuberculosis* growth in the presence of NO but provided 2- to 3-fold greater resistance to H_2O_2 (58, 59). Thus, under conditions of oxidative stress, PknA inhibition of proteasome assembly is able to enhance *M. tuberculosis* resistance to H_2O_2 (56).

M. tuberculosis resistance to nitrosative stress has also been linked to the activity of STPKs. The production of NO in response to cytokines or pathogen-derived molecules is an important host defense mechanism against intracellular pathogens and has been shown to be essential in controlling *M. tuberculosis* infection (60, 61). Although *M. tuberculosis* is able to inhibit the colocalization of inducible nitric oxide synthase (iNOS) to the phagosomal membrane (62), it is unlikely that the bacilli can maintain this inhibition throughout the course of infection. Thus, it would be advantageous for the bacterium to possess additional protective mechanisms to ensure its survival. Deletion of either the *pknE* or *pknH* genes resulted in increased resistance to NO donors (43, 44, 46). However, the increased resistance to nitrosative stress of either mutant coincided with increased sensitivity to the oxidants tested. These findings implicate both PknE and PknH in sensing the host's redox environment and orchestrating a physiological response to enhance the survival of *M. tuberculosis*.

STPKs REGULATE *M. TUBERCULOSIS* MORPHOLOGY TO ENSURE COLONIZATION OF THE HOST

Bacterial proliferation can be thought of in two steps: elongation of the mother cell and division into two daughter cells. In the case of the tubercule bacillus, elongation is characterized by polar growth which requires the synthesis and incorporation of new materials into the cell wall. During the initial stages of infection, *M. tuberculosis* actively replicates inside the macrophage to ensure colonization of the host. The extensive regulation of the mycobacterial cell envelope biogenesis and division results in size and cell wall composition heterogeneity of daughter cells (63, 64). This physicochemical diversity is suggested to increase the survival odds for *M. tuberculosis* by enabling reservoirs within subpopulations that are able withstand diverse dynamic stressors encountered by the bacilli (65).

Cell Size

PknA and PknB have been shown to regulate the growth and morphology of the mycobacterial cell through a number of cell elongation and division proteins (29, 66). PknB is largely involved in regulating cell size through peptidoglycan biosynthesis (Table 1). PknB was shown to inhibit the acetyltransferase activity of GlmU, a protein involved in the synthesis of the peptidoglycan precursor UDP-*N*-acetylglucosamine (67). At the same time, the insertion of lipid II, the final intermediate in peptidoglycan biosynthesis, into the extracellular space is also regulated by PknB. In this situation, the membrane protein MviN responsible for the physical inversion of lipid II is negatively regulated by phosphorylation, ultimately impeding peptidoglycan biosynthesis (68). Furthermore, prior to insertion into the mycobacterial cell wall, lipid II undergoes extensive modification by a family of Mur synthases (69). These synthases are responsible for catalyzing the addition of acetyl, glycosyl, and amino groups to the peptide side chain of lipid II. Modification to peptidoglycan has been described to provide bacteria with resistance to hydrolysis by lysozymes, thereby limiting their detection by host pattern recognition receptors (70) as well as to regulate immunogenicity through the nucleotide-binding oligomerization domain-containing 2 immune receptor (71, 72). Both PknA and PknB have been shown to interact with MurC-F, suggesting that they regulate the modification of muropeptides in response to the environment of *M. tuberculosis* (73, 74).

The final stages of peptidoglycan biosynthesis involve a family of penicillin binding proteins (PBPs) that are responsible for catalyzing cross-linking between peptidoglycan, a modification which also influences cell expansion. Traditionally, peptidoglycan precursors inserted into the cell wall are linked by transpeptidases to produce 4-3 cross-links. In contrast, up to 80% of *M. tuberculosis* peptidoglycan contains 3-3 peptide cross-links (75, 76), and this modification is crucial for persistence *in vivo* (77). Remodeling of peptidoglycan by the PBP DacB1 is believed to be responsible for maintaining 3-3 cross-links. Although the effect of phosphorylation on DacB1 activity is unknown, the PBP is a substrate of PknH *in vitro* (78). It is plausible

that PknH regulates peptidoglycan cross-linking to increases during infection to promote cell wall rigidity and bacterial survival under stress. In addition, the PBP PonA1 is a substrate of PknB. Phosphorylation of PonA1 by PknB inhibits its transglycosylation activity and slows polar elongation, resulting in shorter cells (79). Lastly, PknA also coordinates peptidoglycan biosynthesis through the elongation complex, a macromolecular machine composed of peptidoglycan synthases and hydrolases that drive peptidoglycan remodeling during elongation. To localize elongation to the poles, Wag31 acts as an anchor at this site and provides a basis for the recruitment of the remaining complex components (80). Localization of Wag31 to cell poles is dependent on its phosphorylation by PknA, and growth of the *M. smegmatis* Wag31 phosphomimicking mutant resulted in shorter and wider cells (66).

In contrast to other bacterial species, mycobacterial septa are placed over a wide zone within the cell body (81, 82), further contributing to differences in daughter cell size as well as the distribution of proteins and small molecules between daughter cells (83). FtsZ, a homolog of eukaryotic tubulin, is the principal driving force of cytokinesis in mycobacteria. Through its self-activating GTPase activity, FtsZ undergoes polymerization to form a ring-like structure, known as the Z-ring (84), that was shown to be regulated by PknA among other mechanisms (85). This structure acts as a cytoskeletal scaffold for the recruitment and assembly of the divisome and provides energy for membrane constriction during cell division (86). Phosphorylated FtsZ showed a reduction in GTP hydrolysis and polymerization activity *in vitro*. Overexpression of PknA in *E. coli* resulted in phosphorylation of *E. coli* FtsZ and the production of elongated cells, indicating dysregulation in septum formation (85). In addition, the localization of PbpA, a peptidoglycan synthase part of the divisome, to the septum is thought to be mediated via phosphorylation by PknB (87). PbpA is a substrate of PknB *in vitro*, and the absence of phosphorylated PbpA prevents PbpA localization to the septa and causes the elongated growth of *M. smegmatis in vitro* (87).

As outlined earlier, PknA and PknB play a crucial role in polar elongation and septal localization. Therefore, these two kinases are likely responsible, in part, for differences in the size of daughter cells observed *in vivo*. This notion is supported by the fact that overexpression of these kinases results in short bulging cells, while their depletion causes narrow and elongated bacilli (66). Not only are PknA and PknB essential for *M. tuberculosis* growth *in vitro*, but they also are indispensible in the survival and pathogenesis

of *M. tuberculosis* during murine infection (29, 88) (Table 2). Thus, PknB senses host environmental factors that enable its orchestration of downstream signaling to tightly regulate growth and generate a heterogeneous population that enables *M. tuberculosis* to persist in the presence of host innate and acquired immunity.

Cell Wall Composition

Transcriptional analysis of *M. tuberculosis* isolated from tuberculosis patients identified substantial changes in the expression of cell wall biosynthetic genes, including the upregulation of lipid synthesis genes (89). Thickening of the cell wall restricts the transit of toxic molecules including antibiotics. Lipids can also act as a sink for toxic by-products generated by β-oxidation during *in vivo* growth (90), absorb oxidative radicals (91), and manipulate the host immune response (92). Of these lipids, mycolic acids, phthiocerol dimycocerosate (PDIM), and sulfolipid 1 (SL-1) were all found to increase in abundance and/or alter their composition during *M. tuberculosis* growth *in vivo* (89, 93, 94).

The outer layer of the *M. tuberculosis* cell wall is composed of long-carbon-chain mycolic acids that give rise to the observed thick waxy coat and the remarkable impermeability of mycobacteria (95). The biosynthetic pathway of mycolic acids begins with the *de novo* synthesis of fatty acids from acetyl-CoA. The mycobacterial fatty acid synthase (FAS) II is composed of four sets of enzymes that are essential in catalyzing each cycle of elongation: β-ketoacyl-ACP reductase (MabA), β-hydroxylacyl-ACP dehydratases (HadAB/HadBC), NADH-dependent *trans*-2-enoyl-ACP reductase (InhA), and β-ketoacyl-ACP synthases (KasA or KasB). Interestingly, each FAS-II enzyme is phosphorylated by multiple STPKs (Table 1), enabling regulation of mycolic acid biosynthesis in response to variable growth environments (96–101). STPKs are also involved in reducing the production of the FAS-II system precursors by phosphorylating malonyl-CoA-ACP (FabD) (101) and the β-ketoacyl-ACP synthase (FabH) (102). Being the target of multiple STPKs and the fact that phosphorylation of individual enzymes results in only the partial reduction of its activity enable fine-tuning of the FAS-II system (Table 3). Furthermore, the observation that PknA and PknB negatively regulate these enzymes indicates that even under conditions of growth, mycolic acid biosynthesis is being constrained. Mycolic acid biosynthesis is an expensive process, and in addition, *M. tuberculosis* resides in nutrient-limited phagosomes. Thus, it would be beneficial to carefully balance mycolic acid biosynthesis with cell expansion.

Table 3   Effect of phosphorylation on *M. tuberculosis* serine/threonine protein kinase substrates[a]

Substrate	Function	Effect of phosphorylation	Kinase	References[b]
DosR	Dormancy	Enhances its binding activity to dosR regulon promoter	PknH	27
EF-Tu	Cell division	Reduces interaction with GTP	PknB	190
EgtD	EGT biosynthesis	Inhibits methylation activity	PknD	132
EmbR	Arabinan biosynthesis	Enhances EmbR binding to *embCAB* promoter	PknH	25
FabD	MA biosynthesis	Decreases its condensing activity	PknF	96
FipA	Cell division	Enhances interaction with FtsZ	PknA	179
FtsZ	Cell division	Impairs GTP hydrolysis and polymerization	PknA	85
GarA	TCA cycle	Inhibits binding to KDH, GDH, and GltS	PknB	40, 167
			PknG	40
GlgE	α-glucan biosynthesis	Decreases maltosyltransferase activity	PknB	143
GlmU	PG biosynthesis	Decreases acetyltransferase activity	PknB	67
HupB	Cell division	Inhibits its DNA binding activity	PknE	185
InhA	MA biosynthesis	Decreases enoyl reductase activity	PknA	98
			PknB	98
			PknE	98
			PknL	98
KasB	MA biosynthesis	Decreases its condensing activity	PknF	100
L13	Oxidative stress	Promotes its association with RenU and enhances RenU hydrolysis of NADH	PknG	193
MabA	MA biosynthesis	Decreases β-ketoacyl-ACP reductase activity	PknB	96
Mdh	TCA cycle	Inhibits dehydrogenase activity	PknD	172
MviN	PG biosynthesis	Induces dimerization with FhaA	PknB	68
OprA	Osmotic stress	Enables SigF binding to RNA polymerase	PknD	31
ParB	Cell division	Inhibits DNA binding to *parS* and interaction with ParA	PknA	180
			PknB	180
			PknD	180
			PknF	180
PonA1	PG biosynthesis	Inhibits transglycosylation activity	PknB	79
PrcA	Proteasome	Inhibits proteasome assembly	PknA	56
		Enhances degradation of Ino1	PknB	56
PstP	Signaling	Decreases phosphatase activity	PknA	183
PtpA	Signaling	Enhances phosphatase activity	PknA	51
RshA	Stress response	Inhibits its interaction with SigH	PknB	55
Rv0516c	Anti-antisigma factor?	Inhibits association with Rv268	PknD	30
Rv1747	ABC transporter	Enhances enzymatic activity	PknF	201
Rv2175c	DNA binding?	Inhibits its DNA binding	PknL	26, 197
SahH	Methionine cycle	Decreases hydrolase activity	PknA	182
		Decreases hydrolase activity and its affinity to NAD$^+$	PknB	182, 189
			PknD	182
			PknE	182
			PknF	182
			PknL	182
VirS	MA biosynthesis?	Enhances binding to *mym* promoter under physiological conditions	PknK	14
Wag31	Cell division	Localizes it to the cell poles and enhances oligomerization of the elongation complex	PknA	202

[a]Abbreviations: EGT, ergothioneine; GDH, glutamate dehydrogenase; KDH, α-ketoglutarate dehydrogenase complex; MA, mycolic acid; TCA, tricarboxylic acid; PG, peptidoglycan.
[b]Reference of the effect of phosphorylation on the target substrate identified *in vitro* and/or *in vivo*. Only cases where the effect of phosphorylation by the specific STPK tested and/or phosphorylation sites are mentioned in the table. We do not assume that the STPKs phosphorylate their substrates on the same residues and have the same effect. Table only includes analysis of *M. tuberculosis* proteins.

Differentially regulating FAS-II enzymes may also provide opportunity for the full extension of mycolic acids. The importance of extending these chains has been observed in the *M. tuberculosis kasB* mutant. Production of shorter mycolates in this strain resulted in impaired growth, increased cell wall permeability, and severe defects in resisting host defenses and antibiotic action (103, 104). Lastly, it has also been proposed that mycolic acids are recycled under conditions that damage the cell envelope (105, 106). Consistent with this notion, gene expression profiling of *M. bovis* BCG suggests that "new" mycolic acids are synthesized via the remodeling of older chains during infection (107).

The *mymA* operon (*rv3803-rv3809*) is predicted to encode for the gene products involved in an alternative approach for the condensation of long fatty acids for the synthesis of mycolic acids (108). *M. tuberculosis* disrupted in the *mymA* genes has impaired survival in both activated macrophages and guinea pigs as well as increased cell wall permeability (109). The *mymA* operon has considerable basal activity, which is further enhanced 2- to 3-fold by the transcriptional regulator, VirS, under acidic conditions (14, 109, 110). Interestingly, VirS undergoes posttranslational modification by PknK, enhancing its DNA binding affinity for the *mymA* promoter; however, PknK was only found to stimulate VirS-mediated transcription of the *mym* promoter under physiological conditions (14). Therefore, in the absence of acid stress, PknK may enhance VirS activity, modulating mycolic acid biosynthesis through a FAS-II-independent pathway during infection.

In the past decade, evidence of STPK involvement in PDIM biosynthesis and export has slowly been accumulating. PDIM is implicated in protecting *M. tuberculosis* from reactive nitrogen species generated by the host (111), and thus it is not surprising that PknH, activated by nitrate stress (44, 112), has been found to positively regulate PDIM biosynthesis (113). The exact mechanism behind PknH regulation of PDIM biosynthesis is unknown, but it could be speculated that nitrate stress leads to the downstream activation of PknD and PknE, which have targets in PDIM transport (114) and biosynthesis (115), respectively. In addition to PknE, PknB was also found to phosphorylate PapA5, an acyltransferase that catalyzes the dual esterification of mycocerosate onto phthiocerol to complete the biosynthesis of PDIM (115, 116). Although identified as substrates of *M. tuberculosis* STPKs, it remains unknown what effect phosphorylation has on the activity of PapA5 or the PDIM transporter, MmpL7. Since PknE is also implicated in sensing nitrate stress (43), it is suspected that phosphorylation of PapA5 may positively regulate its enzymatic activity.

PDIM and sulfolipid-1 (SL-1) production are coupled via the metabolic flux of methylmalonyl-coenzyme A (MMCoA) (93), and as a result STPK downregulation of PDIM biosynthesis would lead to an increase in SL-1 production. SL-1 has been found to negatively regulate *M. tuberculosis* growth in human macrophages as well as provide protection against human cationic antimicrobial peptides *in vitro* (117). Enhancing PDIM production via STPK would reduce the quantity of SL-1 (93) while increasing *M. tuberculosis* resistance to reactive nitrogen species (111). The early immune response to *M. tuberculosis* is also subdued by the presence of PDIM, which is shown to inhibit the secretion of tumor necrosis factor-α and interleukin-6 from resting macrophages and dendritic cells (111). Therefore, STPK regulation of PDIM production and export may contribute to the intracellular growth and survival of *M. tuberculosis* during the initial stage of infection.

STPKs COORDINATE *M. TUBERCULOSIS* PHYSIOLOGY TO ACHIEVE NONREPLICATING PERSISTENCE

As the disease progresses, *M. tuberculosis* can further diversify in response to pressure from anatomical location, the host immune response, and drug treatment. These adaptations lead to differences in gene expression profiles, metabolism, growth rate, and other functional characteristics, resulting in a heterogeneous population of bacteria (118). Often, conditions in the host give rise to a subpopulation of dormant-like bacteria characterized as nonreplicating with low metabolic activity. It is these dormant-like bacteria that are the reservoir for *M. tuberculosis* persistence and reactivation of the disease. To successfully enter a dormant-like state, *M. tuberculosis* senses a number of unfavorable growth conditions resulting in growth arrest, cell wall remodeling, and downregulation of metabolism (Fig. 2).

Growth Arrest

M. tuberculosis infection is primarily characterized by the formation of granulomas, organized structures of immune cells that act to control and prevent the dissemination of infection. Despite the heightened immune response that is usually associated with granulomas, *M. tuberculosis* is still able to persist long-term within this structure. Survival under these conditions is likely due to arrested growth and cellular respiration of *M. tuberculosis* in response to NO generated from acti-

Figure 2 *M. tuberculosis* STPK cell signaling network associated with persistence. STPKs sense specific environmental cues (starvation, hypoxia, and nitric oxide) and coordinate a physiological response that triggers *M. tuberculosis* to enter a state of nonreplicating persistence.

vated macrophages and the hypoxic environment of the granuloma (119, 120). The *M. tuberculosis* state of quiescence, termed nonreplicating persistence (NRP), is entered upon the activation of the DosR regulon, a set of 48 genes that downregulate cellular respiration. DosR is regulated by two cognate sensor kinases, DosS and DosT (121, 122), which activate the DosR regulon under conditions of hypoxia (123–125), NO (120), and carbon monoxide (126, 127). Interestingly, PknH was shown to sense host NO and trigger the induction of the DosR regulon (27, 44, 112, 128). Further evidence describes *pknH* transcription to be upregulated during stationary phase growth *in vitro* (129), and the *pknH* deletion mutant showed higher bacillary loads in mouse organs than did wild type (44). Taken together, these

findings implicate PknH in slowing the growth of *M. tuberculosis* to achieve a state of NRP during infection, and perhaps specifically in response to the granuloma's environment (Fig. 2).

The induction of NRP is not limited to the redox environment of *M. tuberculosis*. The other well-known contributing factor leading to NRP is nutrient deprivation (Fig. 2). Both the phagosome and granuloma are sites of nutrient deprivation for pathogens, and *M. tuberculosis* isolated from lung lesions demonstrated an altered morphology and staining properties that were similar to cultures starved in distilled water for 2 years (130). Furthermore, Loebel et al. (131) and Betts et al. (128) identified that starvation of *M. tuberculosis* in phosphate-buffered saline resulted in the gradual shut-

down of respiration to minimal levels, and the bacteria remained viable but nonreplicating. Among the 323 genes involved in adaptation in this model of persistence, *pknB* and *pknD* were both found to be significantly downregulated (128). As a result, it is tempting to speculate that PknB senses the extracellular signal of starvation terminating downstream STPK signaling pathways involved in cell proliferation via posttranslational modification. However, regulation of bacteriostasis by PknB was shown to be specific to oxygen levels, rather than nutrient starvation (33).

PknD also has a functional extracellular domain (32), and its kinase activity is regulated under a variety of processes (Fig. 1), suggesting broad use of this kinase by *M. tuberculosis*. However, the relevance of the downregulation of PknD during nutrient deprivation (128) became apparent when we discovered that PknD negatively regulates ergothioneine biosynthesis in *M. tuberculosis* (132). Ergothioneine is a sulfur-containing amino acid derived from histidine, and very little is known about its physiological role in microorganisms. However, ergothioneine is required for *M. tuberculosis* survival under long-term starvation (132), suggesting that the downregulation of PknD is essential for persistence. In contrast, nutrient starvation (128) and hypoxia (33) show no influence on the transcript levels and activity of PknH *in vitro*.

PknK and PknI have also been implicated in slowing the growth of mycobacteria *in vitro*, which was further shown to be relevant because the *M. tuberculosis* ΔpknK and ΔpknI mutants both demonstrate enhanced growth during macrophage and/or mouse infection (133–135). PknH indirectly regulates the activity of PknK through the signal transduction kinase PknJ (28) (Fig. 1); however, PknK is also positively regulated at a transcriptional level during stationary phase (133). The slowing of *M. tuberculosis* growth is thought to be the consequence of PknK regulating the expression of a variety of genes, including those involved in cell wall processes and lipid metabolism. Perhaps the most notable observation from this study was the inhibitory effect on transcription and translation processes of tRNAs resulting in the repression of protein synthesis in *M. tuberculosis* (134). The exact mechanism of how PknK regulates the expression of a variety of genes is unknown; however, it is plausible that PknK targets a variety of transcriptional regulatory proteins, as observed in the case of VirS (14), to ultimately slow *M. tuberculosis* growth.

PknI is not part of the *M. tuberculosis* STPK interaction network described by Baer et al. (28), and little is known about its activation (Fig. 1). The ΔpknI mutant showed enhanced growth under acidic pH and limited oxygen availability (Table 2), suggesting that PknI is involved in slowing *M. tuberculosis* growth in response to the macrophage environment (135). However, two independent groups have shown that *pknI* expression is not induced upon infection of the macrophage (133, 136), again suggesting that expression data must be interpreted with caution for STPKs. However, it remains possible that PknI expression is not detected during infection because the signaling cascade is only induced at very early stages of infection (<18 h), an event similar to what is observed with PknK (133). Alternatively, the initial expression levels of PknI may be sufficient for its activity within macrophages (135). Currently, there is a single known *in vitro* substrate for PknI: FabD (Table 1); however, the effect of phosphorylation remains to be investigated. In addition, due to its positioning in the *M. tuberculosis* genome, PknI has been proposed to play a role in cell wall synthesis and division (12).

Cell Wall Remodeling

M. tuberculosis halts cell division and undergoes extensive cell wall remodeling while transitioning into a state of NRP (137). Cunningham and Spreadbury (138) reported a very prominent thickening of the cell wall outer layer in *M. tuberculosis*, which was later attributed to the gradual accumulation of loosely bound extracellular material around the bacilli in the form of a capsule (129). This matrix is primarily composed of proteins and polysaccharides (139), with only a small proportion (2 to 3%) containing lipids (140). The major carbohydrates making up 80% of the extracellular capsule are α-glucans, and *M. tuberculosis* strains defective in the production of capsular α-glucans showed attenuated survival in mice during the persistence phase of infection (141).

The biosynthesis of α-glucan in *M. tuberculosis* occurs through three known pathways. Of these, the GlgE pathway has been described as a nonclassical type responsible for the conversion of trehalose into branched α-glucan through maltose 1-phosphate (142). In this pathway the linear backbone of α-glucans is directly synthesized from maltose 1-phosphate by the essential maltosyltransferase, GlgE. To ensure the appropriate channeling of trehalose in the formation of the cell wall, it is expected that the GlgE pathway would be negatively regulated during cell growth. Consistent with this idea, Molle and colleagues (143) identified PknB to negatively regulate GlgE activity and ultimately α-glucan biosynthesis.

Another mechanism employed by *M. tuberculosis* to adapt to a state of NRP is to increase the abundance

of free mycolates in the cell wall lipids (129). Free mycolates have been shown to play a key role in the formation of mycobacterial pellicle biofilms (144), and *M. tuberculosis* biofilms have been observed within the caseum of human granulomas (119). The production of free mycolates occurs as the result of the direct cleavage of trehalose dimycolate (145), and free trehalose is then transported back to the cytoplasm (146). Since *pknB* transcripts are downregulated in the absence of *M. tuberculosis* growth (66, 128), it is plausible that α-glucan biosynthesis via GlgE would thereby increase, contributing to the observed thickening of the *M. tuberculosis* capsule during NRP.

Remodeling of the mycobacterial cell wall during NRP was also found to include increased arabinosylation and abundance of lipoglycans in response to *in vitro* nutrient starvation (129). In mycobacteria, the lipoglycans, lipomannan and lipoarabinomannan (LAM), are associated with the cell wall and are exposed on the outer surface of the bacterium (147). Both of these lipoglycans are ligands of the TLR2; however, lipomannan is a stronger inducer of this receptor's response relative to LAM (148). EmbC is an arabinofuranosyltransferase which serves to elongate the arabinan domain of LAM (149). Transcriptome analyses identified *embC* to be upregulated during stationary phase (129, 149), which most likely contributes to the corresponding increase in LAM arabinosylation observed during NRP (129). The enhanced expression of *embC* is indirectly regulated by PknH through the phosphorylation of the response regulator EmbR (25). Additionally, *pknH* is also upregulated during stationary phase (129). These results implicate PknH in sensing a growth-limiting factor, resulting in a signaling cascade to increase *embC* expression and ultimately the arabinose content of LAM.

In vitro environmental conditions, such as anoxic and nutrient starvation, responsible for directing *M. tuberculosis* into a state of NRP are also found to produce cultures that lose their acid-fastness (130, 150–152). The involvement of mycolic acids in acid-fast staining arose when Jacobs and colleagues (103) observed that the deletion of *kasB* resulted in a loss of acid-fastness. Furthermore, this *M. tuberculosis kasB* mutant displayed significant *in vivo* growth attenuation that led to a long-term persistent infection reminiscent of latent tuberculosis. Prior to these findings, the condensing activities of KasB were found to be under the regulation of STPKs (101), implicating these kinases as major players in the progression of the disease to a latent state. Interestingly, the original study identifying KasB as a substrate of multiple STPKs identified PknA to positively regulate KasB; however, more recent work by the same group showed that phosphorylation of KasB by PknF resulted in shortened mycolic acids that lacked *trans*-cyclopropanation (100). The relevance of the *in vitro* observation of KasB phosphorylation by PknA remains questionable. Nonetheless, further analysis of the KasB phosphomimetic mutant showed a complete loss of acid-fast staining as well as the incapacity to grow yet establish a long-term persistent infection in mice (100).

The core structure of mycolic acids is conserved across mycobacteria; however, pathogenic mycobacteria produce significant quantities of cyclopropanated mycolic acids. Following elongation, the meromycolic chain produced by the FAS-II system can undergo cyclopropanation by a number of *M. tuberculosis* methyltransferases (MmaA 1 to 4, PcaA, and CmaA2). PcaA and MmaA2 have been analyzed for their ability to act as substrates for *M. tuberculosis* STPKs, with only PcaA acting as a substrate for PknF and PknH (153). PcaA methyltransferase activity was decreased upon phosphorylation by PknF. Since *M. tuberculosis* PcaA is implicated in persistence (154) and attenuated immunopathology (155), these findings suggest that mycolic acid modifications have an immunomodulatory function, and specifically, cyclopropanation acts to suppress the immune response to *M. tuberculosis*. However, in the presence of NO, PknH and its downstream signaling effectors, including PknF, are activated, leading to the negative regulation of mycolic acid elongation and cyclopropanation (27, 28). This regulatory mechanism may function to simply act as part of the observed shutdown of mycolic acid biosynthesis when *M. tuberculosis* enters a dormant state (128, 156) and/or may be used to modulate the immune response later in infection (157, 158).

Slowing Central Metabolism

Based on early observations by Bloch and Segal (159), it is accepted that *M. tuberculosis* preferentially utilizes fatty acids as a carbon source during infection. Although the *M. tuberculosis* genome encodes for transporters and enzymes known to metabolize sugars (160), the conditions in which carbohydrates can be utilized for *in vivo* growth still need to be determined. Interestingly, a double mutant of *M. tuberculosis* glucokinases, the enzymes responsible for generating glucose-6-P in the first step of glycolysis, was unable to persist during the chronic phase of infection (161). From these findings, it remains plausible that *M. tuberculosis* has access to glucose during infection; however, the production of glucose-6-P may, rather, be the consequence of gluconeogenesis. The regulatory mechanisms of glucose

metabolism further support the notion that glucose availability is limited inside the host. The activity of the glycolytic enzyme pyruvate kinase A (PykA) has been shown to be a substrate of PknJ in *M. tuberculosis* (162). Although the effect of phosphorylation was not studied in depth, a phosphomutant of PykA suggests negative regulation. As PknJ is activated by PknH, decreasing PykA activity during NRP would impede the production of pyruvate, enabling gluconeogenesis to proceed. Furthermore, glucose transport has also been shown to be mediated by STPKs. *M. tuberculosis* expressing antisense *pknF* demonstrated an increase in [^{14}C]glucose uptake *in vitro* (163). Molle et al. (164) identified Rv1747 to be a substrate of PknF, suggesting that other ABC transporters could be regulated by this mechanism and mediate glucose transport. PknJ (165) and PknF (163) have been shown to decrease the growth rate of *M. bovis* BCG and *M. tuberculosis*, respectively. Perhaps, together PknJ and PknF coordinate the shutdown of carbohydrate catabolism during the *M. tuberculosis* life cycle in the host to slow bacterial growth and prepare the cell for entering a quiescent state.

The observed shutdown of the glycolytic pathway during infection and the inability of carbohydrate transporters to promote the survival of *M. tuberculosis in vivo* suggest that glucose is primarily generated via gluconeogenesis (161). This thought is consistent with the dramatic loss of virulence in a mutant strain that lacks the gluconeogenic enzyme, phosphoenolpyruvate kinase (166). During stationary phase and when grown in nutrient-depleted media, an *M. tuberculosis* mutant deficient in PknG displays reduced growth, and upon further analysis was found to accumulate both glutamate and glutamine (41). Glutamate is one of the major gluconeogenic precursors for cells. The amino acid is broken down by glutamate dehydrogenase to produce α-ketoglutarate and ammonium. A small forkhead associated domain protein known as GarA regulates α-ketoglutarate entry into the tricarboxylic acid (TCA) cycle. GarA binds and inhibits both the α-ketoglutarate dehydrogenase complex and glutamate dehydrogenase (40). In the meantime, GarA also promotes glutamate synthesis by activating glutamine oxoglutarate aminotransferase, an enzyme which assimilates glutamine together with α-ketoglutarate to produce glutamate (167). PknG was shown to phosphorylate GarA and prevent binding to its enzyme partners. Therefore, GarA phosphorylation impedes glutamate synthesis and relieves TCA cycle inhibition in *M. tuberculosis* (40).

PknG has been shown to be upregulated during infection (133) and contribute to the survival of a number of mycobacterial species both in macrophages (39, 168–170) and in mice (41, 168). The macrophage phagosome is presumed to be nutrient-poor, which likely results in the activation of PknG-mediated signaling to upregulate gluconeogenic pathways (Fig. 2). It should be considered that during *in vivo* growth, gluconeogenesis may be acting to support the anabolism of cell wall components, such as mannosylated LAM (171), or other pathways, which in turn results in the blockage of phagosome-lysosome fusion, a phenotype noted earlier to be associated with PknG. A second enzyme involved in gluconeogenesis and the TCA cycle, malate dehydrogenase, is also a substrate of a number of STPKs, including PknD (172). Phosphorylation by PknD has a negative effect on malate dehydrogenase activity. Thus, in conditions resulting in nutrient starvation where *pknD* transcripts are reduced, one would expect an increase in oxaloacetate. In addition, PknD is not required for growth in macrophages (173), indicating that this kinase may also contribute to the regulation of gluconeogenesis during infection.

THE SWITCH: SENSING WHEN TO EXIT NRP

Little is known about the environmental conditions that are associated with the transition between latency and reactivation. Previous work has shown that growth of hypoxia-arrested *M. tuberculosis* occurs upon reaeration of *in vitro* cultures (33, 174). These findings are consistent with anatomically related reactivation, which commonly occurs in the upper lobes, the area of the lungs that have the highest oxygen tension (175), while bacterial dormancy is associated with the oxygen-limited granuloma (176, 177). The regulation of oxygen-dependent replication is mediated in part by PknB (33). PknB protein levels were found to be upregulated in response to oxygen, where PknB decreased during hypoxia. Regulation of bacteriostasis was found to be limited to oxygen, because other conditions known to inhibit growth such as nitric oxide, low pH, and nutrient starvation had no effect on the growth and survival of a *pknB* overexpression strain (33).

The exact mechanism by which PknB senses changes in oxygen tension still needs to be defined, because its extracellular PMP and Ser/Thr Kinase Associated (PASTA) domains are not believed to be involved in oxygen sensing (178). It is thought that *M. tuberculosis* uses resuscitation-promoting factors(Rpfs) to initiate regrowth following dormancy (118). *Micrococcus luteus* Rpf orthologs possess a conserved domain predicted to have lysozyme activity and may therefore cleave peptidoglycan and in turn activate PknB during reaeration.

Alternatively, PknB activation was suggested to go through cross-phosphorylation by another STPK or two-component signaling system in response to oxygen levels (33) as previously exemplified (27).

From the above findings, it is clear that PknB is critical in transducing growth and replication signals in response to oxygen levels. Careful regulation of its activity is required at every stage of the life cycle of *M. tuberculosis*. As suggested, PknB may therefore represent a highly vulnerable drug target for *M. tuberculosis* during both active and latent disease.

CONCLUSION

To establish persistence, *M. tuberculosis* STPKs regulate mycobacterial proteins to adapt the bacilli's physiology. Furthermore, to ensure survival inside the phagosome, *M. tuberculosis* interferes with the host intracellular signaling of the infected macrophage through the secreted phosphatases PtpA and SapM. Currently, little evidence exists that demonstrates secretion and direct association of *M. tuberculosis* STPKs with host effector proteins. Rather, the role STPKs play in evading the host immune response is mainly through the regulation of cell growth, cell wall remodeling, and the activation of specific stress responses during infection.

Generally, as shown in Table 1, multiple STPKs can act on a defined single substrate and have a similar effect, suggesting that *M. tuberculosis* carefully fine-tunes its physiological response to match the associated conditions of the bacterium. In addition, multiple enzymes that belong to the same pathway or cell process are also regulated by multiple STPKs. Such regulatory flexibility can lead to a population differing in cell size, growth rate, and cell wall composition. As a result, the heterogeneity of this population may improve the fitness of *M. tuberculosis* by providing bacteria with the physiological diversity to successfully grow in a range of host microenvironments or persist in a quiescent state.

Currently, our knowledge of the conditions that activate STPKs during infection is limited. Therefore, it is difficult to link the physiological adaptation of *M. tuberculosis* with the host response. We can predict that *M. tuberculosis* replicates during the initial stage of infection as well as during disease reactivation, a process which is regulated for the most part by PknA and PknB. However, under conditions of limited oxygen and nutrients as well as in the presence of NO, *M. tuberculosis* enters a state of NRP to ensure its long-term survival in the host. Although these conditions can be encountered at any point during the life cycle of the bacilli, *M. tuberculosis* primarily exists in a state of NRP in the granuloma. As summarized in Fig. 2, the hypoxic environment of the granuloma likely shuts down PknB and its downstream signaling pathway to arrest growth and increase peptidoglycan and α-glucan biosynthesis to enhance rigidity and thickness, respectively, of the cell wall. In parallel, *de novo* biosynthesis of mycolic acids is downregulated by both the activation of PknH and the inhibition of PknB signaling cascades to potentially reduce *M. tuberculosis* immunogenicity. The activation of PknH by NO generated from activated macrophages additionally enhances the induction of the DosR regulon to further prevent bacterial replication and inhibit aerobic respiration. In addition to DosR, PknH coordinates slowing of *M. tuberculosis* growth through PknJ and its downstream targets PknF and PknK to inhibit glucose catabolism and protein synthesis. Despite reduced metabolic activity during NRP, *M. tuberculosis* relies on gluconeogenesis for biomass production and survival throughout infection. It is likely that PknG plays a crucial role in this process through its regulation of GarA. Furthermore, the downregulation of PknD is potentially crucial for the survival of *M. tuberculosis* during NRP due to its role in gluconeogenesis and ergothioneine biosynthesis.

Understanding the mechanisms behind host signaling pathways targeted by *M. tuberculosis*, as well as how the bacilli physiologically adapt to persist within the host, is crucial for effective management of chronic infection. In the past two decades, the field of oncology has been dedicated to developing libraries of compounds that block protein kinase activity due to their role in uncontrolled cell division. Therefore, it may be possible to use our knowledge of how *M. tuberculosis* interferes with host signaling pathways and enhance the immune response with an appropriate compound. Alternatively, screening these libraries for antimicrobial activity against *M. tuberculosis* may also prove beneficial. Because *M. tuberculosis* STPKs play a crucial role in regulating a wide variety of cell processes involved in bacterial growth and persistence, altering the activity of these kinases may represent a promising approach for novel drug discovery.

Citation. Richard-Greenblatt M, Av-Gay Y. 2017. Epigenetic phosphorylation control of *Mycobacterium tuberculosis* infection and persistence. Microbiol Spectrum 5(2):TBTB2-0005-2015.

References

1. **Wang JY, Koshland DE Jr.** 1978. Evidence for protein kinase activities in the prokaryote *Salmonella typhimurium*. *J Biol Chem* **253**:7605–7608.

2. **Garnak M, Reeves HC.** 1979. Phosphorylation of isocitrate dehydrogenase of *Escherichia coli*. *Science* **203**:1111–1112.

3. **Manai M, Cozzone AJ.** 1979. Analysis of the protein-kinase activity of *Escherichia coli* cells. *Biochem Biophys Res Commun* **91**:819–826.

4. **Mizuno T, Wurtzel ET, Inouye M.** 1982. Osmoregulation of gene expression. II. DNA sequence of the envZ gene of the ompB operon of *Escherichia coli* and characterization of its gene product. *J Biol Chem* **257**:13692–13698.

5. **Tommassen J, de Geus P, Lugtenberg B, Hackett J, Reeves P.** 1982. Regulation of the pho regulon of Escherichia coli K-12: cloning of the regulatory genes phoB and phoR and identification of their gene products. *J Mol Biol* **157**:265–274.

6. **Grebe TW, Stock JB.** 1999. The histidine protein kinase superfamily. *Adv Microb Physiol* **41**:139–227.

7. **Kannan N, Taylor SS, Zhai Y, Venter JC, Manning G.** 2007. Structural and functional diversity of the microbial kinome. *PLoS Biol* **5**:e17.

8. **Chao J, Wong D, Zheng X, Poirier V, Bach H, Hmama Z, Av-Gay Y.** 2010. Protein kinase and phosphatase signaling in *Mycobacterium tuberculosis* physiology and pathogenesis. *Biochim Biophys Acta* **1804**:620–627.

9. **Wong D, Chao JD, Av-Gay Y.** 2013. *Mycobacterium tuberculosis*-secreted phosphatases: from pathogenesis to targets for TB drug development. *Trends Microbiol* **21**:100–109.

10. **Prisic S, Husson RN.** 2014. Mycobacterium tuberculosis serine/threonine protein kinases. *Microbiol Spectr* **2**:2.

11. **Sickmann A, Meyer HE.** 2001. Phosphoamino acid analysis. *Proteomics* **1**:200–206.

12. **Av-Gay Y, Everett M.** 2000. The eukaryotic-like Ser/Thr protein kinases of *Mycobacterium tuberculosis*. *Trends Microbiol* **8**:238–244.

13. **Alber T.** 2009. Signaling mechanisms of the *Mycobacterium tuberculosis* receptor Ser/Thr protein kinases. *Curr Opin Struct Biol* **19**:650–657.

14. **Kumar P, Kumar D, Parikh A, Rananaware D, Gupta M, Singh Y, Nandicoori VK.** 2009. The *Mycobacterium tuberculosis* protein kinase K modulates activation of transcription from the promoter of mycobacterial monooxygenase operon through phosphorylation of the transcriptional regulator VirS. *J Biol Chem* **284**:11090–11099.

15. **Koul A, Choidas A, Treder M, Tyagi AK, Drlica K, Singh Y, Ullrich A.** 2000. Cloning and characterization of secretory tyrosine phosphatases of *Mycobacterium tuberculosis*. *J Bacteriol* **182**:5425–5432.

16. **Bach H, Papavinasasundaram KG, Wong D, Hmama Z, Av-Gay Y.** 2008. *Mycobacterium tuberculosis* virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. *Cell Host Microbe* **3**:316–322.

17. **Bach H, Ko HH, Raizman EA, Attarian R, Cho B, Biet F, Enns R, Bressler B.** 2011. Immunogenicity of *Mycobacterium avium* subsp. *paratuberculosis* proteins in Crohn's disease patients. *Scand J Gastroenterol* **46**:30–39.

18. **Chow K, Ng D, Stokes R, Johnson P.** 1994. Protein tyrosine phosphorylation in *Mycobacterium tuberculosis*. *FEMS Microbiol Lett* **124**:203–207.

19. **Bach H, Wong D, Av-Gay Y.** 2009. *Mycobacterium tuberculosis* PtkA is a novel protein tyrosine kinase whose substrate is PtpA. *Biochem J* **420**:155–162.

20. **Kusebauch U, Ortega C, Ollodart A, Rogers RS, Sherman DR, Moritz RL, Grundner C.** 2014. *Mycobacterium tuberculosis* supports protein tyrosine phosphorylation. *Proc Natl Acad Sci USA* **111**:9265–9270.

21. **Chao KL, Gorlatova NV, Eisenstein E, Herzberg O.** 2014. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein. *J Biol Chem* **289**:29948–29960.

22. **Zhou P, Wong D, Li W, Xie J, Av-Gay Y.** 2015. Phosphorylation of *Mycobacterium tuberculosis* protein tyrosine kinase A PtkA by Ser/Thr protein kinases. *Biochem Biophys Res Commun* **467**:421–426.

23. **Prisic S, Dankwa S, Schwartz D, Chou MF, Locasale JW, Kang CM, Bemis G, Church GM, Steen H, Husson RN.** 2010. Extensive phosphorylation with overlapping specificity by *Mycobacterium tuberculosis* serine/threonine protein kinases. *Proc Natl Acad Sci USA* **107**:7521–7526.

24. **Jünger MA, Aebersold R.** 2014. Mass spectrometry-driven phosphoproteomics: patterning the systems biology mosaic. *Wiley Interdiscip Rev Dev Biol* **3**:83–112.

25. **Sharma K, Gupta M, Pathak M, Gupta N, Koul A, Sarangi S, Baweja R, Singh Y.** 2006. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, *in vivo*. *J Bacteriol* **188**:2936–2944.

26. **Cohen-Gonsaud M, Barthe P, Canova MJ, Stagier-Simon C, Kremer L, Roumestand C, Molle V.** 2009. The *Mycobacterium tuberculosis* Ser/Thr kinase substrate Rv2175c is a DNA-binding protein regulated by phosphorylation. *J Biol Chem* **284**:19290–19300.

27. **Chao JD, Papavinasasundaram KG, Zheng X, Chávez-Steenbock A, Wang X, Lee GQ, Av-Gay Y.** 2010. Convergence of Ser/Thr and two-component signaling to coordinate expression of the dormancy regulon in *Mycobacterium tuberculosis*. *J Biol Chem* **285**:29239–29246.

28. **Baer CE, Iavarone AT, Alber T, Sassetti CM.** 2014. Biochemical and spatial coincidence in the provisional Ser/Thr protein kinase interaction network of *Mycobacterium tuberculosis*. *J Biol Chem* **289**:20422–20433.

29. **Nagarajan SN, Upadhyay S, Chawla Y, Khan S, Naz S, Subramanian J, Gandotra S, Nandicoori VK.** 2015. Protein kinase A (PknA) of *Mycobacterium tuberculosis* is independently activated and is critical for growth *in vitro* and survival of the pathogen in the host. *J Biol Chem* **290**:9626–9645.

30. **Greenstein AE, MacGurn JA, Baer CE, Falick AM, Cox JS, Alber T.** 2007. *M. tuberculosis* Ser/Thr protein kinase D phosphorylates an anti-anti-sigma factor homolog. *PLoS Pathog* **3:**e49.

31. **Hatzios SK, Baer CE, Rustad TR, Siegrist MS, Pang JM, Ortega C, Alber T, Grundner C, Sherman DR, Bertozzi CR.** 2013. Osmosensory signaling in *Mycobacterium tuberculosis* mediated by a eukaryotic-like Ser/Thr protein kinase. *Proc Natl Acad Sci USA* **110:** E5069–E5077.

32. **Good MC, Greenstein AE, Young TA, Ng HL, Alber T.** 2004. Sensor domain of the *Mycobacterium tuberculosis* receptor Ser/Thr protein kinase, PknD, forms a highly symmetric beta propeller. *J Mol Biol* **339:**459–469.

33. **Ortega C, Liao R, Anderson LN, Rustad T, Ollodart AR, Wright AT, Sherman DR, Grundner C.** 2014. *Mycobacterium tuberculosis* Ser/Thr protein kinase B mediates an oxygen-dependent replication switch. *PLoS Biol* **12:** e1001746.

34. **Armstrong JA, Hart PD.** 1971. Response of cultured macrophages to *Mycobacterium tuberculosis*, with observations on fusion of lysosomes with phagosomes. *J Exp Med* **134:**713–740.

35. **Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG.** 1994. Lack of acidification in *Mycobacterium* phagosomes produced by exclusion of the vesicular proton-ATPase. *Science* **263:**678–681.

36. **Poirier V, Bach H, Av-Gay Y.** 2014. *Mycobacterium tuberculosis* promotes anti-apoptotic activity of the macrophage by PtpA protein-dependent dephosphorylation of host GSK3α. *J Biol Chem* **289:**29376–29385.

37. **Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y.** 2011. *Mycobacterium tuberculosis* protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification. *Proc Natl Acad Sci USA* **108:** 19371–19376.

38. **Wang J, Li BX, Ge PP, Li J, Wang Q, Gao GF, Qiu XB, Liu CH.** 2015. *Mycobacterium tuberculosis* suppresses innate immunity by coopting the host ubiquitin system. *Nat Immunol* **16:**237–245.

39. **Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, Huygen K, Klebl B, Thompson C, Bacher G, Pieters J.** 2004. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. *Science* **304:**1800–1804.

40. **O'Hare HM, Durán R, Cerveñansky C, Bellinzoni M, Wehenkel AM, Pritsch O, Obal G, Baumgartner J, Vialaret J, Johnsson K, Alzari PM.** 2008. Regulation of glutamate metabolism by protein kinases in mycobacteria. *Mol Microbiol* **70:**1408–1423.

41. **Cowley S, Ko M, Pick N, Chow R, Downing KJ, Gordhan BG, Betts JC, Mizrahi V, Smith DA, Stokes RW, Av-Gay Y.** 2004. The *Mycobacterium tuberculosis* protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth *in vivo*. *Mol Microbiol* **52:**1691–1702.

42. **Keane J, Remold HG, Kornfeld H.** 2000. Virulent *Mycobacterium tuberculosis* strains evade apoptosis of infected alveolar macrophages. *J Immunol* **164:**2016–2020.

43. **Jayakumar D, Jacobs WR Jr, Narayanan S.** 2008. Protein kinase E of *Mycobacterium tuberculosis* has a role in the nitric oxide stress response and apoptosis in a human macrophage model of infection. *Cell Microbiol* **10:**365–374.

44. **Papavinasasundaram KG, Chan B, Chung JH, Colston MJ, Davis EO, Av-Gay Y.** 2005. Deletion of the *Mycobacterium tuberculosis* pknH gene confers a higher bacillary load during the chronic phase of infection in BALB/c mice. *J Bacteriol* **187:**5751–5760.

45. **Li CQ, Wogan GN.** 2005. Nitric oxide as a modulator of apoptosis. *Cancer Lett* **226:**1–15.

46. **Kumar D, Narayanan S.** 2012. pknE, a serine/threonine kinase of *Mycobacterium tuberculosis* modulates multiple apoptotic paradigms. *Infect Genet Evol* **12:** 737–747.

47. **Parandhaman DK, Hanna LE, Narayanan S.** 2014. PknE, a serine/threonine protein kinase of *Mycobacterium tuberculosis* initiates survival crosstalk that also impacts HIV coinfection. *PLoS One* **9:**e83541.

48. **Sequeira PC, Senaratne RH, Riley LW.** 2014. Inhibition of toll-like receptor 2 (TLR-2)-mediated response in human alveolar epithelial cells by mycolic acids and *Mycobacterium tuberculosis* mce1 operon mutant. *Pathog Dis* **70:**132–140.

49. **Sánchez D, Rojas M, Hernández I, Radzioch D, García LF, Barrera LF.** 2010. Role of TLR2- and TLR4-mediated signaling in *Mycobacterium tuberculosis*-induced macrophage death. *Cell Immunol* **260:**128–136.

50. **Nuzzo I, Galdiero M, Bentivoglio C, Galdiero R, Romano Carratelli C.** 2002. Apoptosis modulation by mycolic acid, tuberculostearic acid and trehalose 6,6′-dimycolate. *J Infect* **44:**229–235.

51. **Zhou P, Li W, Wong D, Xie J, Av-Gay Y.** 2015. Phosphorylation control of protein tyrosine phosphatase A activity in *Mycobacterium tuberculosis*. *FEBS Lett* **589:** 326–331.

52. **Vishwanath V, Meera R, Narayanan PR, Puvanakrishnan R.** 1997. Fate of *Mycobacterium tuberculosis* inside rat peritoneal macrophages *in vitro*. *Mol Cell Biochem* **175:** 169–175.

53. **Sachdeva P, Misra R, Tyagi AK, Singh Y.** 2010. The sigma factors of *Mycobacterium tuberculosis*: regulation of the regulators. *FEBS J* **277:**605–626.

54. **Song T, Dove SL, Lee KH, Husson RN.** 2003. RshA, an anti-sigma factor that regulates the activity of the mycobacterial stress response sigma factor SigH. *Mol Microbiol* **50:**949–959.

55. **Park ST, Kang CM, Husson RN.** 2008. Regulation of the SigH stress response regulon by an essential protein kinase in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* **105:**13105–13110.

56. **Anandan T, Han J, Baun H, Nyayapathy S, Brown JT, Dial RL, Moltalvo JA, Kim MS, Yang SH, Ronning DR, Husson RN, Suh J, Kang CM.** 2014. Phosphorylation regulates mycobacterial proteasome. *J Microbiol* **52:** 743–754.

57. **Festa RA, McAllister F, Pearce MJ, Mintseris J, Burns KE, Gygi SP, Darwin KH.** 2010. Prokaryotic ubiquitin-

like protein (Pup) proteome of *Mycobacterium tuberculosis*. *PLoS One* **5:**e8589.

58. **Darwin KH, Ehrt S, Gutierrez-Ramos JC, Weich N, Nathan CF.** 2003. The proteasome of *Mycobacterium tuberculosis* is required for resistance to nitric oxide. *Science* **302:**1963–1966.

59. **Gandotra S, Schnappinger D, Monteleone M, Hillen W, Ehrt S.** 2007. *In vivo* gene silencing identifies the *Mycobacterium tuberculosis* proteasome as essential for the bacteria to persist in mice. *Nat Med* **13:**1515–1520.

60. **MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF.** 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc Natl Acad Sci USA* **94:**5243–5248.

61. **Miller CC, Rawat M, Johnson T, Av-Gay Y.** 2007. Innate protection of *Mycobacterium smegmatis* against the antimicrobial activity of nitric oxide is provided by mycothiol. *Antimicrob Agents Chemother* **51:**3364–3366.

62. **Davis AS, Vergne I, Master SS, Kyei GB, Chua J, Deretic V.** 2007. Mechanism of inducible nitric oxide synthase exclusion from mycobacterial phagosomes. *PLoS Pathog* **3:**e186.

63. **Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, Fortune SM.** 2012. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. *Science* **335:**100–104.

64. **Santi I, Dhar N, Bousbaine D, Wakamoto Y, McKinney JD.** 2013. Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria. *Nat Commun* **4:**2470.

65. **Kieser KJ, Rubin EJ.** 2014. How sisters grow apart: mycobacterial growth and division. *Nat Rev Microbiol* **12:**550–562.

66. **Kang CM, Abbott DW, Park ST, Dascher CC, Cantley LC, Husson RN.** 2005. The *Mycobacterium tuberculosis* serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. *Genes Dev* **19:**1692–1704.

67. **Parikh A, Verma SK, Khan S, Prakash B, Nandicoori VK.** 2009. PknB-mediated phosphorylation of a novel substrate, *N*-acetylglucosamine-1-phosphate uridyltransferase, modulates its acetyltransferase activity. *J Mol Biol* **386:**451–464.

68. **Gee CL, Papavinasasundaram KG, Blair SR, Baer CE, Falick AM, King DS, Griffin JE, Venghatakrishnan H, Zukauskas A, Wei JR, Dhiman RK, Crick DC, Rubin EJ, Sassetti CM, Alber T.** 2012. A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. *Sci Signal* **5:**ra7.

69. **Mahapatra S, Yagi T, Belisle JT, Espinosa BJ, Hill PJ, McNeil MR, Brennan PJ, Crick DC.** 2005. Mycobacterial lipid II is composed of a complex mixture of modified muramyl and peptide moieties linked to decaprenyl phosphate. *J Bacteriol* **187:**2747–2757.

70. **Davis KM, Weiser JN.** 2011. Modifications to the peptidoglycan backbone help bacteria to establish infection. *Infect Immun* **79:**562–570.

71. **Hansen JM, Golchin SA, Veyrier FJ, Domenech P, Boneca IG, Azad AK, Rajaram MV, Schlesinger LS, Divangahi M, Reed MB, Behr MA.** 2014. *N*-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of *Mycobacterium tuberculosis*. *J Infect Dis* **209:**1045–1054.

72. **Coulombe F, Divangahi M, Veyrier F, de Léséleuc L, Gleason JL, Yang Y, Kelliher MA, Pandey AK, Sassetti CM, Reed MB, Behr MA.** 2009. Increased NOD2-mediated recognition of *N*-glycolyl muramyl dipeptide. *J Exp Med* **206:**1709–1716.

73. **Munshi T, Gupta A, Evangelopoulos D, Guzman JD, Gibbons S, Keep NH, Bhakta S.** 2013. Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in *Mycobacterium tuberculosis*. *PLoS One* **8:**e60143.

74. **Thakur M, Chakraborti PK.** 2008. Ability of PknA, a mycobacterial eukaryotic-type serine/threonine kinase, to transphosphorylate MurD, a ligase involved in the process of peptidoglycan biosynthesis. *Biochem J* **415:**27–33.

75. **Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, Boshoff HI, Barry CE III.** 2012. Meropenem inhibits D,D-carboxypeptidase activity in *Mycobacterium tuberculosis*. *Mol Microbiol* **86:**367–381.

76. **Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL.** 2008. The peptidoglycan of stationary-phase *Mycobacterium tuberculosis* predominantly contains cross-links generated by L,D-transpeptidation. *J Bacteriol* **190:**4360–4366.

77. **Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G.** 2010. The *Mycobacterium tuberculosis* protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. *Nat Med* **16:**466–469.

78. **Zheng X, Papavinasasundaram KG, Av-Gay Y.** 2007. Novel substrates of *Mycobacterium tuberculosis* PknH Ser/Thr kinase. *Biochem Biophys Res Commun* **355:**162–168.

79. **Kieser KJ, Boutte CC, Kester JC, Baer CE, Barczak AK, Meniche X, Chao MC, Rego EH, Sassetti CM, Fortune SM, Rubin EJ.** 2015. Phosphorylation of the peptidoglycan synthase PonA1 governs the rate of polar elongation in mycobacteria. *PLoS Pathog* **11:**e1005010.

80. **Meniche X, Otten R, Siegrist MS, Baer CE, Murphy KC, Bertozzi CR, Sassetti CM.** 2014. Subpolar addition of new cell wall is directed by DivIVA in mycobacteria. *Proc Natl Acad Sci USA* **111:**E3243–E3251.

81. **Joyce G, Williams KJ, Robb M, Noens E, Tizzano B, Shahrezaei V, Robertson BD.** 2012. Cell division site placement and asymmetric growth in mycobacteria. *PLoS One* **7:**e44582.

82. **Singh B, Nitharwal RG, Ramesh M, Pettersson BM, Kirsebom LA, Dasgupta S.** 2013. Asymmetric growth and division in *Mycobacterium* spp.: compensatory mechanisms for non-medial septa. *Mol Microbiol* **88:**64–76.

83. **Kysela DT, Brown PJ, Huang KC, Brun YV.** 2013. Biological consequences and advantages of asymmetric bacterial growth. *Annu Rev Microbiol* **67:**417–435.

84. **Adams DW, Errington J.** 2009. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. *Nat Rev Microbiol* **7:**642–653.

85. **Thakur M, Chakraborti PK.** 2006. GTPase activity of mycobacterial FtsZ is impaired due to its transphosphorylation by the eukaryotic-type Ser/Thr kinase, PknA. *J Biol Chem* **281:**40107–40113.

86. **Typas A, Banzhaf M, Gross CA, Vollmer W.** 2011. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. *Nat Rev Microbiol* **10:**123–136.

87. **Dasgupta A, Datta P, Kundu M, Basu J.** 2006. The serine/threonine kinase PknB of *Mycobacterium tuberculosis* phosphorylates PBPA, a penicillin-binding protein required for cell division. *Microbiology* **152:**493–504. [Retraction,]

88. **Chawla Y, Upadhyay S, Khan S, Nagarajan SN, Forti F, Nandicoori VK.** 2014. Protein kinase B (PknB) of *Mycobacterium tuberculosis* is essential for growth of the pathogen *in vitro* as well as for survival within the host. *J Biol Chem* **289:**13858–13875.

89. **Rachman H, Strong M, Ulrichs T, Grode L, Schuchhardt J, Mollenkopf H, Kosmiadi GA, Eisenberg D, Kaufmann SH.** 2006. Unique transcriptome signature of *Mycobacterium tuberculosis* in pulmonary tuberculosis. *Infect Immun* **74:**1233–1242.

90. **Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM.** 2012. Cholesterol catabolism by *Mycobacterium tuberculosis* requires transcriptional and metabolic adaptations. *Chem Biol* **19:**218–227.

91. **Dubnau E, Chan J, Raynaud C, Mohan VP, Lanéelle MA, Yu K, Quémard A, Smith I, Daffé M.** 2000. Oxygenated mycolic acids are necessary for virulence of *Mycobacterium tuberculosis* in mice. *Mol Microbiol* **36:**630–637.

92. **Vander Beken S, Al Dulayymi JR, Naessens T, Koza G, Maza-Iglesias M, Rowles R, Theunissen C, De Medts J, Lanckacker E, Baird MS, Grooten J.** 2011. Molecular structure of the *Mycobacterium tuberculosis* virulence factor, mycolic acid, determines the elicited inflammatory pattern. *Eur J Immunol* **41:**450–460.

93. **Jain M, Petzold CJ, Schelle MW, Leavell MD, Mougous JD, Bertozzi CR, Leary JA, Cox JS.** 2007. Lipidomics reveals control of *Mycobacterium tuberculosis* virulence lipids via metabolic coupling. *Proc Natl Acad Sci USA* **104:**5133–5138.

94. **Bhamidi S, Shi L, Chatterjee D, Belisle JT, Crick DC, McNeil MR.** 2012. A bioanalytical method to determine the cell wall composition of *Mycobacterium tuberculosis* grown *in vivo*. *Anal Biochem* **421:**240–249.

95. **Barry CE III, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, Yuan Y.** 1998. Mycolic acids: structure, biosynthesis and physiological functions. *Prog Lipid Res* **37:**143–179.

96. **Veyron-Churlet R, Zanella-Cléon I, Cohen-Gonsaud M, Molle V, Kremer L.** 2010. Phosphorylation of the *Mycobacterium tuberculosis* beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. *J Biol Chem* **285:**12714–12725.

97. **Molle V, Gulten G, Vilchèze C, Veyron-Churlet R, Zanella-Cléon I, Sacchettini JC, Jacobs WR Jr, Kremer L.** 2010. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of *Mycobacterium tuberculosis*. *Mol Microbiol* **78:**1591–1605.

98. **Khan S, Nagarajan SN, Parikh A, Samantaray S, Singh A, Kumar D, Roy RP, Bhatt A, Nandicoori VK.** 2010. Phosphorylation of enoyl-acyl carrier protein reductase InhA impacts mycobacterial growth and survival. *J Biol Chem* **285:**37860–37871.

99. **Slama N, Leiba J, Eynard N, Daffé M, Kremer L, Quémard A, Molle V.** 2011. Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from *Mycobacterium tuberculosis* type II fatty acid synthase system. *Biochem Biophys Res Commun* **412:**401–406.

100. **Vilchèze C, Molle V, Carrère-Kremer S, Leiba J, Mourey L, Shenai S, Baronian G, Tufariello J, Hartman T, Veyron-Churlet R, Trivelli X, Tiwari S, Weinrick B, Alland D, Guérardel Y, Jacobs WR Jr, Kremer L.** 2014. Phosphorylation of KasB regulates virulence and acid-fastness in *Mycobacterium tuberculosis*. *PLoS Pathog* **10:**e1004115.

101. **Molle V, Brown AK, Besra GS, Cozzone AJ, Kremer L.** 2006. The condensing activities of the *Mycobacterium tuberculosis* type II fatty acid synthase are differentially regulated by phosphorylation. *J Biol Chem* **281:**30094–30103.

102. **Veyron-Churlet R, Molle V, Taylor RC, Brown AK, Besra GS, Zanella-Cléon I, Fütterer K, Kremer L.** 2009. The *Mycobacterium tuberculosis* beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue. *J Biol Chem* **284:**6414–6424.

103. **Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, Chen B, Chan J, Porcelli SA, Kobayashi K, Besra GS, Jacobs WR Jr.** 2007. Deletion of kasB in *Mycobacterium tuberculosis* causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. *Proc Natl Acad Sci USA* **104:**5157–5162.

104. **Gao LY, Laval F, Lawson EH, Groger RK, Woodruff A, Morisaki JH, Cox JS, Daffe M, Brown EJ.** 2003. Requirement for kasB in i mycolic acid biosynthesis, cell wall impermeability and intracellular survival: implications for therapy. *Mol Microbiol* **49:**1547–1563.

105. **Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK.** 1999. Exploring drug-induced alterations in gene expression in *Mycobacterium tuberculosis* by microarray hybridization. *Proc Natl Acad Sci USA* **96:**12833–12838.

106. **Voskuil MI.** 2013. *Mycobacterium tuberculosis* cholesterol catabolism requires a new class of acyl coenzyme A dehydrogenase. *J Bacteriol* **195:**4319–4321.

107. **Rienksma RA, Suarez-Diez M, Mollenkopf HJ, Dolganov GM, Dorhoi A, Schoolnik GK, Martins Dos Santos VA, Kaufmann SH, Schaap PJ, Gengenbacher M.** 2015. Comprehensive insights into transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing. *BMC Genomics* **16:**34.

108. **Asselineau C, Asselineau J, Lanéelle G, Lanéelle MA.** 2002. The biosynthesis of mycolic acids by mycobac-

teria: current and alternative hypotheses. *Prog Lipid Res* **41**:501–523.

109. **Singh A, Gupta R, Vishwakarma RA, Narayanan PR, Paramasivan CN, Ramanathan VD, Tyagi AK.** 2005. Requirement of the mymA operon for appropriate cell wall ultrastructure and persistence of *Mycobacterium tuberculosis* in the spleens of guinea pigs. *J Bacteriol* **187**:4173–4186.

110. **Singh A, Jain S, Gupta S, Das T, Tyagi AK.** 2003. mymA operon of *Mycobacterium tuberculosis*: its regulation and importance in the cell envelope. *FEMS Microbiol Lett* **227**:53–63.

111. **Rousseau C, Winter N, Pivert E, Bordat Y, Neyrolles O, Avé P, Huerre M, Gicquel B, Jackson M.** 2004. Production of phthiocerol dimycocerosates protects *Mycobacterium tuberculosis* from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. *Cell Microbiol* **6**:277–287.

112. **Sharma K, Chandra H, Gupta PK, Pathak M, Narayan A, Meena LS, D'Souza RC, Chopra P, Ramachandran S, Singh Y.** 2004. PknH, a transmembrane Hank's type serine/threonine kinase from *Mycobacterium tuberculosis* is differentially expressed under stress conditions. *FEMS Microbiol Lett* **233**:107–113.

113. **Gómez-Velasco A, Bach H, Rana AK, Cox LR, Bhatt A, Besra GS, Av-Gay Y.** 2013. Disruption of the serine/ threonine protein kinase H affects phthiocerol dimycocerosates synthesis in *Mycobacterium tuberculosis*. *Microbiology* **159**:726–736.

114. **Pérez J, Garcia R, Bach H, de Waard JH, Jacobs WR Jr, Av-Gay Y, Bubis J, Takiff HE.** 2006. *Mycobacterium tuberculosis* transporter MmpL7 is a potential substrate for kinase PknD. *Biochem Biophys Res Commun* **348**:6–12.

115. **Touchette MH, Bommineni GR, Delle Bovi RJ, Gadbery JE, Nicora CD, Shukla AK, Kyle JE, Metz TO, Martin DW, Sampson NS, Miller WT, Tonge PJ, Seeliger JC.** 2015. Diacyltransferase activity and chain length specificity of *Mycobacterium tuberculosis* PapA5 in the synthesis of alkyl β-diol lipids. *Biochemistry* **54**:5457–5468.

116. **Gupta M, Sajid A, Arora G, Tandon V, Singh Y.** 2009. Forkhead-associated domain-containing protein Rv0019c and polyketide-associated protein PapA5, from substrates of serine/threonine protein kinase PknB to interacting proteins of *Mycobacterium tuberculosis*. *J Biol Chem* **284**:34723–34734.

117. **Gilmore SA, Schelle MW, Holsclaw CM, Leigh CD, Jain M, Cox JS, Leary JA, Bertozzi CR.** 2012. Sulfolipid-1 biosynthesis restricts *Mycobacterium tuberculosis* growth in human macrophages. *ACS Chem Biol* **7**:863–870.

118. **Gengenbacher M, Kaufmann SH.** 2012. *Mycobacterium tuberculosis*: success through dormancy. *FEMS Microbiol Rev* **36**:514–532.

119. **Canetti G.** 1955. The tubercle bacillus in the pulmonary lesion of man, p 111–126. *In* Dubos RJ, McDermott W (ed), *Growth of the Tubercle Bacillus in the Tuberculosis Lesion*. Springer, New York, NY.

120. **Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK.** 2003. Inhibition of respiration by nitric oxide induces a *Mycobacterium tuberculosis* dormancy program. *J Exp Med* **198**:705–713.

121. **Saini DK, Malhotra V, Tyagi JS.** 2004. Cross talk between DevS sensor kinase homologue, Rv2027c, and DevR response regulator of *Mycobacterium tuberculosis*. *FEBS Lett* **565**:75–80.

122. **Kumar A, Toledo JC, Patel RP, Lancaster JR Jr, Steyn AJ.** 2007. *Mycobacterium tuberculosis* DosS is a redox sensor and DosT is a hypoxia sensor. *Proc Natl Acad Sci USA* **104**:11568–11573.

123. **Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK.** 2001. Regulation of the *Mycobacterium tuberculosis* hypoxic response gene encoding alpha-crystallin. *Proc Natl Acad Sci USA* **98**:7534–7539. [Erratum,]

124. **Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR.** 2003. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of *Mycobacterium tuberculosis*. *Mol Microbiol* **48**:833–843.

125. **Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE III, Andersen P.** 2002. Hypoxic response of *Mycobacterium tuberculosis* studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. *J Bacteriol* **184**:3485–3491.

126. **Kumar A, Deshane JS, Crossman DK, Bolisetty S, Yan BS, Kramnik I, Agarwal A, Steyn AJ.** 2008. Heme oxygenase-1-derived carbon monoxide induces the *Mycobacterium tuberculosis* dormancy regulon. *J Biol Chem* **283**:18032–18039.

127. **Shiloh MU, Manzanillo P, Cox JS.** 2008. *Mycobacterium tuberculosis* senses host-derived carbon monoxide during macrophage infection. *Cell Host Microbe* **3**:323–330.

128. **Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K.** 2002. Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol Microbiol* **43**:717–731.

129. **Bacon J, Alderwick LJ, Allnutt JA, Gabasova E, Watson R, Hatch KA, Clark SO, Jeeves RE, Marriott A, Rayner E, Tolley H, Pearson G, Hall G, Besra GS, Wernisch L, Williams A, Marsh PD.** 2014. Non-replicating *Mycobacterium tuberculosis* elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. *PLoS One* **9**:e87329.

130. **Nyka W.** 1974. Studies on the effect of starvation on mycobacteria. *Infect Immun* **9**:843–850.

131. **Loebel RO, Shorr E, Richardson HB.** 1933. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. *J Bacteriol* **26**:167–200.

132. **Richard-Greenblatt M, Bach H, Adamson J, Peña-Diaz S, Li W, Steyn AJ, Av-Gay Y.** 2015. Regulation of ergothioneine biosynthesis and its effect on *Mycobacterium tuberculosis* growth and infectivity. *J Biol Chem* **290**:23064–23076.

133. Malhotra V, Arteaga-Cortés LT, Clay G, Clark-Curtiss JE. 2010. *Mycobacterium tuberculosis* protein kinase K confers survival advantage during early infection in mice and regulates growth in culture and during persistent infection: implications for immune modulation. *Microbiology* **156:**2829–2841.

134. Malhotra V, Okon BP, Clark-Curtiss JE. 2012. *Mycobacterium tuberculosis* protein kinase K enables growth adaptation through translation control. *J Bacteriol* **194:** 4184–4196.

135. Gopalaswamy R, Narayanan S, Chen B, Jacobs WR, Av-Gay Y. 2009. The serine/threonine protein kinase PknI controls the growth of *Mycobacterium tuberculosis* upon infection. *FEMS Microbiol Lett* **295:** 23–29.

136. Singh A, Singh Y, Pine R, Shi L, Chandra R, Drlica K. 2006. Protein kinase I of *Mycobacterium tuberculosis*: cellular localization and expression during infection of macrophage-like cells. *Tuberculosis (Edinb)* **86:**28–33.

137. Rittershaus ES, Baek SH, Sassetti CM. 2013. The normalcy of dormancy: common themes in microbial quiescence. *Cell Host Microbe* **13:**643–651.

138. Cunningham AF, Spreadbury CL. 1998. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. *J Bacteriol* **180:**801–808.

139. Ortalo-Magné A, Dupont MA, Lemassu A, Andersen AB, Gounon P, Daffé M. 1995. Molecular composition of the outermost capsular material of the tubercle bacillus. *Microbiology* **141:**1609–1620.

140. Ortalo-Magné A, Lemassu A, Lanéelle MA, Bardou F, Silve G, Gounon P, Marchal G, Daffé M. 1996. Identification of the surface-exposed lipids on the cell envelopes of *Mycobacterium tuberculosis* and other mycobacterial species. *J Bacteriol* **178:**456–461.

141. Sambou T, Dinadayala P, Stadthagen G, Barilone N, Bordat Y, Constant P, Levillain F, Neyrolles O, Gicquel B, Lemassu A, Daffé M, Jackson M. 2008. Capsular glucan and intracellular glycogen of *Mycobacterium tuberculosis*: biosynthesis and impact on the persistence in mice. *Mol Microbiol* **70:**762–774.

142. Chandra G, Chater KF, Bornemann S. 2011. Unexpected and widespread connections between bacterial glycogen and trehalose metabolism. *Microbiology* **157:** 1565–1572.

143. Leiba J, Syson K, Baronian G, Zanella-Cléon I, Kalscheuer R, Kremer L, Bornemann S, Molle V. 2013. *Mycobacterium tuberculosis* maltosyltransferase GlgE, a genetically validated antituberculosis target, is negatively regulated by Ser/Thr phosphorylation. *J Biol Chem* **288:**16546–16556.

144. Ojha AK, Baughn AD, Sambandan D, Hsu T, Trivelli X, Guerardel Y, Alahari A, Kremer L, Jacobs WR Jr, Hatfull GF. 2008. Growth of *Mycobacterium tuberculosis* biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. *Mol Microbiol* **69:**164–174.

145. Ojha AK, Trivelli X, Guerardel Y, Kremer L, Hatfull GF. 2010. Enzymatic hydrolysis of trehalose dimycolate releases free mycolic acids during mycobacterial growth in biofilms. *J Biol Chem* **285:**17380–17389.

146. Kalscheuer R, Weinrick B, Veeraraghavan U, Besra GS, Jacobs WR Jr. 2010. Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* **107:**21761–21766.

147. Pitarque S, Larrouy-Maumus G, Payré B, Jackson M, Puzo G, Nigou J. 2008. The immunomodulatory lipoglycans, lipoarabinomannan and lipomannan, are exposed at the mycobacterial cell surface. *Tuberculosis (Edinb)* **88:**560–565.

148. Vignal C, Guérardel Y, Kremer L, Masson M, Legrand D, Mazurier J, Elass E. 2003. Lipomannans, but not lipoarabinomannans, purified from *Mycobacterium chelonae* and *Mycobacterium kansasii* induce TNF-alpha and IL-8 secretion by a CD14-toll-like receptor 2-dependent mechanism. *J Immunol* **171:**2014–2023.

149. Goude R, Amin AG, Chatterjee D, Parish T. 2008. The critical role of embC in *Mycobacterium tuberculosis*. *J Bacteriol* **190:**4335–4341.

150. Deb C, Lee CM, Dubey VS, Daniel J, Abomoelak B, Sirakova TD, Pawar S, Rogers L, Kolattukudy PE. 2009. A novel *in vitro* multiple-stress dormancy model for *Mycobacterium tuberculosis* generates a lipid-loaded, drug-tolerant, dormant pathogen. *PLoS One* **4:**e6077.

151. Gillespie J, Barton LL, Rypka EW. 1986. Phenotypic changes in mycobacteria grown in oxygen-limited conditions. *J Med Microbiol* **21:**251–255.

152. Daniel J, Maamar H, Deb C, Sirakova TD, Kolattukudy PE. 2011. *Mycobacterium tuberculosis* uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. *PLoS Pathog* **7:**e1002093.

153. Corrales RM, Molle V, Leiba J, Mourey L, de Chastellier C, Kremer L. 2012. Phosphorylation of mycobacterial PcaA inhibits mycolic acid cyclopropanation: consequences for intracellular survival and for phagosome maturation block. *J Biol Chem* **287:**26187–26199.

154. Rao V, Fujiwara N, Porcelli SA, Glickman MS. 2005. *Mycobacterium tuberculosis* controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. *J Exp Med* **201:**535–543.

155. Glickman MS, Cox JS, Jacobs WR Jr. 2000. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of *Mycobacterium tuberculosis*. *Mol Cell* **5:**717–727.

156. Galagan JE, Minch K, Peterson M, Lyubetskaya A, Azizi E, Sweet L, Gomes A, Rustad T, Dolganov G, Glotova I, Abeel T, Mahwinney C, Kennedy AD, Allard R, Brabant W, Krueger A, Jaini S, Honda B, Yu WH, Hickey MJ, Zucker J, Garay C, Weiner B, Sisk P, Stolte C, Winkler JK, Van de Peer Y, Iazzetti P, Camacho D, Dreyfuss J, Liu Y, Dorhoi A, Mollenkopf HJ, Drogaris P, Lamontagne J, Zhou Y, Piquenot J, Park ST, Raman S, Kaufmann SH, Mohney RP, Chelsky D, Moody DB, Sherman DR, Schoolnik GK. 2013. The *Mycobacterium tuberculosis* regulatory network and hypoxia. *Nature* **499:**178–183.

157. Barkan D, Hedhli D, Yan HG, Huygen K, Glickman MS. 2012. *Mycobacterium tuberculosis* lacking all

mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. *Infect Immun* **80:**1958–1968.

158. **Barkan D, Liu Z, Sacchettini JC, Glickman MS.** 2009. Mycolic acid cyclopropanation is essential for viability, drug resistance, and cell wall integrity of *Mycobacterium tuberculosis. Chem Biol* **16:**499–509.

159. **Bloch H, Segal W.** 1956. Biochemical differentiation of *Mycobacterium tuberculosis* grown *in vivo* and *in vitro. J Bacteriol* **72:**132–141.

160. **Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE III, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG.** 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393:**537–544.

161. **Marrero J, Trujillo C, Rhee KY, Ehrt S.** 2013. Glucose phosphorylation is required for *Mycobacterium tuberculosis* persistence in mice. *PLoS Pathog* **9:**e1003116.

162. **Arora G, Sajid A, Gupta M, Bhaduri A, Kumar P, Basu-Modak S, Singh Y.** 2010. Understanding the role of PknJ in *Mycobacterium tuberculosis*: biochemical characterization and identification of novel substrate pyruvate kinase A. *PLoS One* **5:**e10772.

163. **Deol P, Vohra R, Saini AK, Singh A, Chandra H, Chopra P, Das TK, Tyagi AK, Singh Y.** 2005. Role of *Mycobacterium tuberculosis* Ser/Thr kinase PknF: implications in glucose transport and cell division. *J Bacteriol* **187:**3415–3420.

164. **Molle V, Soulat D, Jault JM, Grangeasse C, Cozzone AJ, Prost JF.** 2004. Two FHA domains on an ABC transporter, Rv1747, mediate its phosphorylation by PknF, a Ser/Thr protein kinase from *Mycobacterium tuberculosis. FEMS Microbiol Lett* **234:**215–223.

165. **Singh DK, Singh PK, Tiwari S, Singh SK, Kumari R, Tripathi DK, Srivastava KK.** 2014. Phosphorylation of pyruvate kinase A by protein kinase J leads to the altered growth and differential rate of intracellular survival of mycobacteria. *Appl Microbiol Biotechnol* **98:**10065–10076.

166. **Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S.** 2010. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for *Mycobacterium tuberculosis* to establish and maintain infection. *Proc Natl Acad Sci USA* **107:**9819–9824.

167. **Nott TJ, Kelly G, Stach L, Li J, Westcott S, Patel D, Hunt DM, Howell S, Buxton RS, O'Hare HM, Smerdon SJ.** 2009. An intramolecular switch regulates phosphoindependent FHA domain interactions in *Mycobacterium tuberculosis. Sci Signal* **2:**ra12.

168. **Tiwari D, Singh RK, Goswami K, Verma SK, Prakash B, Nandicoori VK.** 2009. Key residues in *Mycobacterium tuberculosis* protein kinase G play a role in regulating kinase activity and survival in the host. *J Biol Chem* **284:**27467–27479.

169. **Chaurasiya SK, Srivastava KK.** 2009. Downregulation of protein kinase C-alpha enhances intracellular survival of mycobacteria: role of PknG. *BMC Microbiol* **9:**271.

170. **Scherr N, Müller P, Perisa D, Combaluzier B, Jenö P, Pieters J.** 2009. Survival of pathogenic mycobacteria in macrophages is mediated through autophosphorylation of protein kinase G. *J Bacteriol* **191:**4546–4554.

171. **Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, DesJardin LE, Schlesinger LS.** 2005. The human macrophage mannose receptor directs *Mycobacterium tuberculosis* lipoarabinomannan-mediated phagosome biogenesis. *J Exp Med* **202:**987–999.

172. **Wang XM, Soetaert K, Peirs P, Kalai M, Fontaine V, Dehaye JP, Lefèvre P.** 2015. Biochemical analysis of the NAD+-dependent malate dehydrogenase, a substrate of several serine/threonine protein kinases of *Mycobacterium tuberculosis. PLoS One* **10:**e0123327.

173. **Be NA, Bishai WR, Jain SK.** 2012. Role of *Mycobacterium tuberculosis* pknD in the pathogenesis of central nervous system tuberculosis. *BMC Microbiol* **12:**7.

174. **Wayne LG.** 1977. Synchronized replication of *Mycobacterium tuberculosis. Infect Immun* **17:**528–530.

175. **Schmitt SK, Longworth DL.** 2014. Pulmonary infections, 505–524. *In* Kacmarek RM, Stoller JK, Heuer A (ed), *Egan's Fundamentals of Respiratory Care*, 10th ed. Elsevier Health Sciences, St. Louis, MO.

176. **Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, Tufariello J, Flynn J, Chan J.** 2006. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. *Cell Microbiol* **8:**218–232.

177. **Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE III.** 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. *Infect Immun* **76:**2333–2340.

178. **Barthe P, Mukamolova GV, Roumestand C, Cohen-Gonsaud M.** 2010. The structure of PknB extracellular PASTA domain from *Mycobacterium tuberculosis* suggests a ligand-dependent kinase activation. *Structure* **18:** 606–615.

179. **Sureka K, Hossain T, Mukherjee P, Chatterjee P, Datta P, Kundu M, Basu J.** 2010. Novel role of phosphorylation-dependent interaction between FtsZ and FipA in mycobacterial cell division. *PLoS One* **5:**e8590.

180. **Baronian G, Ginda K, Berry L, Cohen-Gonsaud M, Zakrzewska-Czerwińska J, Jakimowicz D, Molle V.** 2015. Phosphorylation of *Mycobacterium tuberculosis* ParB participates in regulating the ParABS chromosome segregation system. *PLoS One* **10:**e0119907.

181. **Sharma K, Gupta M, Krupa A, Srinivasan N, Singh Y.** 2006. EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in *Mycobacterium tuberculosis. FEBS J* **273:**2711–2721.

182. **Corrales RM, Leiba J, Cohen-Gonsaud M, Molle V, Kremer L.** 2013. *Mycobacterium tuberculosis* S-adenosyl-l-homocysteine hydrolase is negatively regulated by Ser/

Thr phosphorylation. *Biochem Biophys Res Commun* **430:**858–864.

183. **Sajid A, Arora G, Gupta M, Upadhyay S, Nandicoori VK, Singh Y.** 2011. Phosphorylation of *Mycobacterium tuberculosis* Ser/Thr phosphatase by PknA and PknB. *PLoS One* **6:**e17871.

184. **Canova MJ, Kremer L, Molle V.** 2009. The *Mycobacterium tuberculosis* GroEL1 chaperone is a substrate of Ser/Thr protein kinases. *J Bacteriol* **191:**2876–2883.

185. **Gupta M, Sajid A, Sharma K, Ghosh S, Arora G, Singh R, Nagaraja V, Tandon V, Singh Y.** 2014. HupB, a nucleoid-associated protein of *Mycobacterium tuberculosis*, is modified by serine/threonine protein kinases *in vivo*. *J Bacteriol* **196:**2646–2657.

186. **Grundner C, Gay LM, Alber T.** 2005. *Mycobacterium tuberculosis* serine/threonine kinases PknB, PknD, PknE, and PknF phosphorylate multiple FHA domains. *Protein Sci* **14:**1918–1921.

187. **Roumestand C, Leiba J, Galophe N, Margeat E, Padilla A, Bessin Y, Barthe P, Molle V, Cohen-Gonsaud M.** 2011. Structural insight into the *Mycobacterium tuberculosis* Rv0020c protein and its interaction with the PknB kinase. *Structure* **19:**1525–1534.

188. **Villarino A, Duran R, Wehenkel A, Fernandez P, England P, Brodin P, Cole ST, Zimny-Arndt U, Jungblut PR, Cerveñansky C, Alzari PM.** 2005. Proteomic identification of *M. tuberculosis* protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions. *J Mol Biol* **350:**953–963.

189. **Singhal A, Arora G, Sajid A, Maji A, Bhat A, Virmani R, Upadhyay S, Nandicoori VK, Sengupta S, Singh Y.** 2013. Regulation of homocysteine metabolism by *Mycobacterium tuberculosis* S-adenosylhomocysteine hydrolase. *Sci Rep* **3:**2264.

190. **Sajid A, Arora G, Gupta M, Singhal A, Chakraborty K, Nandicoori VK, Singh Y.** 2011. Interaction of *Mycobacterium tuberculosis* elongation factor Tu with GTP is regulated by phosphorylation. *J Bacteriol* **193:**5347–5358.

191. **Corrales RM, Molle V, Leiba J, Mourey L, de Chastellier C, Kremer L.** 2012. Phosphorylation of mycobacterial PcaA inhibits mycolic acid cyclopropanation: consequences for intracellular survival and for phagosome maturation block. *J Biol Chem* **287:**26187–26199.

192. **Molle V, Reynolds RC, Alderwick LJ, Besra GS, Cozzone AJ, Fütterer K, Kremer L.** 2008. EmbR2, a structural homologue of EmbR, inhibits the *Mycobacterium tuberculosis* kinase/substrate pair PknH/EmbR. *Biochem J* **410:**309–317.

193. **Wolff KA, de la Peña AH, Nguyen HT, Pham TH, Amzel LM, Gabelli SB, Nguyen L.** 2015. A redox regulatory system critical for mycobacterial survival in macrophages and biofilm development. *PLoS Pathog* **11:**e1004839.

194. **Molle V, Kremer L, Girard-Blanc C, Besra GS, Cozzone AJ, Prost JF.** 2003. An FHA phosphoprotein recognition domain mediates protein EmbR phosphorylation by PknH, a Ser/Thr protein kinase from *Mycobacterium tuberculosis*. *Biochemistry* **42:**15300–15309.

195. **Jang J, Stella A, Boudou F, Levillain F, Darthuy E, Vaubourgeix J, Wang C, Bardou F, Puzo G, Gilleron M, Burlet-Schiltz O, Monsarrat B, Brodin P, Gicquel B, Neyrolles O.** 2010. Functional characterization of the *Mycobacterium tuberculosis* serine/threonine kinase PknJ. *Microbiology* **156:**1619–1631.

196. **Kumari R, Saxena R, Tiwari S, Tripathi DK, Srivastava KK.** 2013. Rv3080c regulates the rate of inhibition of mycobacteria by isoniazid through FabD. *Mol Cell Biochem* **374:**149–155.

197. **Canova MJ, Veyron-Churlet R, Zanella-Cleon I, Cohen-Gonsaud M, Cozzone AJ, Becchi M, Kremer L, Molle V.** 2008. The *Mycobacterium tuberculosis* serine/threonine kinase PknL phosphorylates Rv2175c: mass spectrometric profiling of the activation loop phosphorylation sites and their role in the recruitment of Rv2175c. *Proteomics* **8:**521–533.

198. **Rifat D, Bishai WR, Karakousis PC.** 2009. Phosphate depletion: a novel trigger for *Mycobacterium tuberculosis* persistence. *J Infect Dis* **200:**1126–1135.

199. **Vanzembergh F, Peirs P, Lefevre P, Celio N, Mathys V, Content J, Kalai M.** 2010. Effect of PstS sub-units or PknD deficiency on the survival of *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)* **90:**338–345.

200. **Kumar D, Palaniyandi K, Challu VK, Kumar P, Narayanan S.** 2013. PknE, a serine/threonine protein kinase from *Mycobacterium tuberculosis* has a role in adaptive responses. *Arch Microbiol* **195:**75–80.

201. **Spivey VL, Molle V, Whalan RH, Rodgers A, Leiba J, Stach L, Walker KB, Smerdon SJ, Buxton RS.** 2011. Forkhead-associated (FHA) domain containing ABC transporter Rv1747 is positively regulated by Ser/Thr phosphorylation in *Mycobacterium tuberculosis*. *J Biol Chem* **286:**26198–26209.

202. **Jani C, Eoh H, Lee JJ, Hamasha K, Sahana MB, Han JS, Nyayapathy S, Lee JY, Suh JW, Lee SH, Rehse SJ, Crick DC, Kang CM.** 2010. Regulation of polar peptidoglycan biosynthesis by Wag31 phosphorylation in mycobacteria. *BMC Microbiol* **10:**327.